Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
ROLE OF INTERCELLULAR INTERACTIONS BETWEEN MAST CELLS AND GINGIVAL FIBROBLASTS IN
MEDIATING INFLAMMTION
by
Reza Termei
A thesis submitted in conformity with the requirements for the degree of Master of Science
Graduate Department of Dentistry University of Toronto
© Copyright by Reza Termei 2011
ROLE OF INTERCELLULAR INTERACTIONS BETWEEN MAST CELLS AND GINGIVAL FIBROBLASTS IN MEDIATING
INFLAMMTION
Reza Termei
Master of Science
Graduate Department of Dentistry
University of Toronto
2011
Abstract
The mechanisms that mediate acute exacerbations in chronic inflammatory diseases such as
periodontitis are not understood. IL-8 is a potent chemoattractant for neutrophils in acute
inflammatory lesions. We investigated the role of fibroblast-mast cell interactions on short-term
IL-8 release. Human gingival fibroblasts were co-cultured with human mast cells (HMC-1).
After co-culture, the concentration of IL-8 was measured by ELISA. HMC co-cultured with
fibroblasts increased IL-8 secretion by >6-fold, which required intercellular contact and was
blocked by the gap junction inhibitor BGA. Thapsigargin-induced elevations of intracellular
calcium increased IL-8 levels by 15-fold. Chemotaxis of human neutrophils was significantly
enhanced in response to conditioned medium from co-cultures. Calcein-dye transfer showed
intercellular, gap junction communication between HMC and fibroblasts that was dependent in
part on 1 integrins. We conclude that mast cells adhere to fibroblasts and promote IL-8
secretion, thereby enhancing neutrophil chemotaxis and possibly the perpetuation of the
inflammatory response.
ii.
Acknowledgements
I extend my sincere thanks to all of those people who supported me over the past two years, in
particular the following individuals, since without their support and assistance the completion of
my project would not have been possible:
My supervisor, Christopher McCulloch for his continuous encouragement, invaluable
guidance and brilliant ideas. He is a true example of a dedicated supervisor.
My advisory committee Michael Glogauer and Boris Hinz for their insight, support and
constructive suggestions in the preparation of this thesis.
Carol Laschinger for teaching me the laboratory techniques and for her troubleshooting
advice. She also played a significant role in this project in assisting with the cytokine arrays
and conducting dose-response, time-course and bead binding experiments.
Wilson Lee for performing the flow cytometry experiments and for investigating role of
integrins in cell binding.
Pam Arora for answering my technical questions and for her assistance throughout my
project.
Chunxiang Sun for her contribution in the neutrophil chemotaxis assay.
Cheung Lo for teaching me the principles of cell culturing.
Matthew Chan, Hugh Kim and Ibrahim Mohammad for their friendship and help which
made my lab experience filled with nothing but good memories.
My parents, for their unfailing love and support throughout my life.
My wife, Yeganeh, for her unconditional love, patience and never ending encouragement
during the last two years.
iii.
TABLE OF CONTENTS
ABSTRACT……………………………………………………………….……………………..ii
ACKNOWLEDGEMENTS………………………………........................…………………… iii
TABLE OF CONTENTS……………………………………………........................……….…iv
LIST OF FIGURES…………………………………………..………..........................……......vi
Chapter 1: Literature Review...….....…...………………...…........................….1
1. Periodontal diseases………………………………………………….…..........................1
a. Periodontitis and systemic diseases ………………………………………………….1
b. Microbial challenge ………………………………………………………………...…2
c. Early steps of the pathogenic process in periodontitis………………….. …………….3
d. Mechanisms of tissue destruction in periodontitis…………………………….………4
e. Natural history of periodontitis………………………………………………………..…….. 5
2. Neutrophils……………………………………………………………………………… 7
a. Function……………………………..……………………………………………...……..7
b. Role of neutrophils in periodontal diseases ….…………………………………...…...9
3. Chemokines……….………………………………………………….…........................10
a. Structure and nomenclature ………………………………………………………….10
b. Biology of IL-8……..……………………………………………………………...…13
c. IL-8 production……………………………………………………….. …………… .13
d. IL-8 receptors and function……………………..……………………………..……..…14
e. IL-8 in periodontitis………….…………………………………………………………….. 14
4. Fibroblasts……….…………………..……………………………….…........................15
a. Intercellular adhesion ………………………………………….………………….….16
5. Mast cells……….………………………….………………………….…........................17
a. Origin and physiology ………………………………………………………………..17
b. Mast cell mediators ..……………………………………………………………...….18
c. Mast cell proliferation and activation ………………………………...……………...20
d. Immune function .………………………………..………………………………………21
e. Angiogenesis..……..……….…………………………….………………………….. 21
f. Mast cells and T-lymphocytes….……………………………………..………….…..22
iv.
g. Mast cells and fibroblasts.................... .........................................................................23
Statement of the problem………….…………………………………........………..........…25
Chapter 2: Role of intercellular interactions between mast cells and gingival
fibroblasts in mediating inflammation…….…………………………………………………..27
Introduction…….……………………………………………………………………….. 27
Materials and Methods………...…………………………………………………………29
Results……………………………………………………………………………………38
Discussion………………………………………………………………………………..43
Figures and Legends…..…………………………………………………………………51
References…………………………………..…………………………………………………...63
v.
List of Figures
Figure 1……………………………………………………………...............................................11
Figure 2……………………………………………………………...............................................20
Figure 3……………………………………………………………...............................................22
Figure 4……………………………………………………………...............................................33
Figure 5……………………………………………………………...............................................51
Figure 6……………………………………………………………...............................................53
Figure 7……………………………………………………………...............................................55
Figure 8……………………………………………………………...............................................57
Figure 9……………………………………………………………...............................................59
Figure 10…………………………………………………………….............................................61
vi.
1
Chapter 1: Literature Review
1. Periodontal diseases
In general, periodontal diseases are divided into two main clinical categories, gingivitis
and periodontitis. Gingivitis is the diagnosis that is provided for conditions in which there is
inflammation of gingival tissue around teeth but without involvement of the attachment
apparatus [1]. In contrast, periodontitis is the diagnosis for lesions in which inflammation
extends into the periodontal ligament and is associated with bone loss [1]. Periodontitis is the
second most prevalent infectious disease in North American human populations and has been
sub-categorized into aggressive, chronic or systemic periodontitis. Aggressive periodontitis is
characterized by rapid tissue destruction and periodontal attachment loss in which the severity of
destruction is not consistent with the abundance of bacterial biofilms. In comparison to
aggressive periodontitis, the rate of progression is slower for chronic periodontitis, which is the
most common form of periodontitis and affects over 30% of the U.S. adult population [2], [3],
[4].
a. Periodontitis and systemic diseases
Over the past two decades increasing evidence has suggested positive associations
between periodontal inflammation and several important systemic diseases. Periodontitis is
positively associated with cardiovascular diseases, atherosclerosis, myocardial infarction and
stroke [5], [6]. Notably, periodontal treatment can improve glycemic control in diabetic patients
[7]. In pregnant women, periodontal diseases may be a risk factor for pre-term and/or low-birth
weight infants [8]. Further, periodontitis may be associated with increased risk of respiratory
diseases such as chronic obstructive pulmonary disease and nosocomial pneumonia [9], [10].
One longitudinal study showed that periodontal diseases were associated with a small but
2
significant increase in the overall risk of developing cancer; these associations were also found in
patients who had never smoked [11].
b. Microbial challenge
Periodontitis is an infectious disease, but other genetic and environmental factors also
affect its severity and outcome [12], [13]. Among the hundreds of bacterial species that reside
within subgingival biofilms, A. actinomycetemcomitans, Porphyromonas gingivalis, Tannerella
forsythensis and Treponema denticola are particularly associated with progressive periodontitis
[14]. Subgingival biofilms exhibit organizational and structural features of communities [15] and
individual species often exhibit extensive collaborative strategies for survival and
communication [16]. Bacterial behaviour in biofilms is markedly different from bacteria in the
planktonic state; pathogenicity and virulence are often markedly increased in biofilms [16].
Within subgingival biofilms, some species facilitate the growth and survival of other
species, which might explain the aggregation of certain specific species in complexes that are
associated with progressive lesions [17], [18]. As periodontal pathogens are typically found in
subgingival biofilms, the prevention and treatment of periodontitis by antibiotics is often
hampered because the shielding effect of the biofilm surface layers enhances the resistance of
bacteria to locally or systemically delivered antibiotics [16].
Biofilms resist attack by the innate immune response. For example, some bacteria within
the biofilm (e.g. P. gingivalis) can impair neutrophil responses by inhibiting their adhesion
capacity to bacteria [19], a process that increases bacterial survival. Physical disruption, for
example by scaling and root planing, is one of the most effective approaches for treatment of
bacterial biofilms in the periodontal environment [20] and the very large positive effect that is
seen clinically after debridement is probably a result of the disruption of the structure and
3
therefore the pathogenic potential of the biofilm. A common observation in many
microbiological studies of periodontal infections is that not all patients harbouring periodontal
pathogens develop periodontitis. This observation underlines the important effect of host-
modifying factors in the pathogenesis of periodontitis.
c. Early steps of the pathogenic process in periodontitis
One of the most important sites of initial confrontation between the host immune system
and bacteria associated with pathogenic biofilms is in the gingival crevice. When the abundance
or the pathogenic potential of the subgingival bacterial challenge is increased, microbial
metabolites can affect the structural integrity and metabolism of the junctional epithelium and
underlying lamina propria of the gingival connective tissue, thereby causing an increase in
vascular permeability. One of the hallmarks of the resulting inflammatory process is the
enhanced infiltration and migration of neutrophils into the gingival crevice in response to
chemokines such as IL-8 [21], [22], [23], [24]. If the bacterial challenge is maintained, after a
few days, signs of inflammation will be manifested as redness and swelling of the marginal
gingiva. In many patients, host immune mechanisms may contain the growth and the maturation
of the subgingival biofilm, thereby preventing its spread to deeper regions of the periodontium.
At inflamed periodontal sites, the lesion is referred to as gingivitis. If the microbial challenge is
not contained by the host response, microbial-induced inflammation can mediate tissue
destruction within the periodontium, which may affect the supporting structures of the teeth. At
these sites, the lesion is referred to as periodontitis [25]. Although gingivitis is thought to
represent the initial phase in the natural history of periodontitis, one theory of disease
progression posits that gingivitis is a separate entity and may be stable (the so-called “established
lesion”) and may not progress [24]. Previous hypothesis papers focusing on the importance of the
4
inflammatory response have suggested that host response factors play the key role in the
pathogenesis of periodontitis while bacterial virulence may be responsible for only about 20% of
periodontal disease cases [15], [26], [27].
d. Mechanisms of tissue destruction in periodontitis
In response to bacterial lipopolysaccharides, which are thought to be important virulence
factors in periodontitis, macrophages may express and secrete inflammatory cytokines including
IL-1β, prostaglandins, TNFα and the important tissue degrading family of enzymes, the matrix
metalloproteinases (MMPs). IL-1β and TNFα can activate fibroblasts to enhance expression of
MMPs and prostaglandin E2 [28]. MMPs, which are also produced by other cell types including
neutrophils, fibroblasts, epithelial and endothelial cells, can mediate degradation of extracellular
matrix molecules like collagen [29] while PGE2 can enhance bone resorption [30]. One of the
effects of periodontal tissue destruction is that bacterial biofilms may extend further apically and
laterally into the gingival connective tissue, a process that can lead to deepening of the gingival
crevice and creation of periodontal pockets [31], [32]. As the disease progresses, inflammatory
infiltrates replace the normal structure of the lamina propria of the gingival and of the
periodontal ligament [24]. These progressive lesions are also associated with an increase in the
proportion of gram negative anaerobic bacteria within subgingival plaques [18]. Although some
putative periodontal pathogens (e.g. P. gingivalis) can release bacterial enzymes like collagenase
(bacterial collagenase), nearly all of the collagenases found in periodontally diseased tissues are
derived from host cells and not from bacteria [33], [34], [35].
Cytokines, prostaglandins and chemokines are thought to be important regulators of the
inflammatory responses that characterize periodontitis. Bacteria in subgingival biofilms probably
contribute to periodontal tissue destruction by attracting and activating host cells that produce
5
these inflammatory mediators [33], [36], [37]. Notably, patterns of cytokine abundance in
gingival crevicular fluid may be markedly different between periodontally active and stable sites
[38], [39], [40]. Conceivably, periodontal lesions can be perpetuated, blocked or possibly
reversed as a result of the biological activity of these host modifying factors. Arising from these
hypotheses and observations, some treatment approaches have been suggested that involve
inhibition of the degradation of the extracellular matrix by pharmacological intervention as a
viable therapeutic modality [29].
e. Natural history of periodontitis
Early models of the natural history of periodontitis suggested that the rate of destruction
of bone and periodontal ligament was continuous over time [41]. Slowly progressive attachment
loss was thought to occur throughout adult life, which in some cases may have lead to tooth loss
if treatment was not provided. However, a series of longitudinal studies undertaken 25-30 years
ago at the Forsyth Institute (Boston) suggested that the natural history of periodontitis may be
more aptly characterized as a heterogeneous group of diseases in which recurrent episodes of
acute exacerbation and tissue destruction alternate with longer periods of quiescence. During the
acute exacerbations, there was thought to be increased rate of attachment loss [42]. The bursts of
activity seemed to occur randomly at different sites while at the same time, most other
periodontal sites in the same mouth showed no disease activity. The exact mechanism of disease
destruction that may account for the observations from the Forsyth group are not defined, but,
according to our current understanding of periodontitis, it may be explained by fluctuations in
the efficacy of the host immune response. However, it should be noted that the Forsyth model of
rare, site-specific, acute exacerbations of attachment loss could be artefactual and may be
explained by the manner in which attachment levels were measured. Notably, because of errors
6
associated with clinical measurement of gingival attachment level, the investigators at the
Forsyth used very high thresholds of attachment loss (>2.5 mm) to define whether or not
attachment loss had actually occurred at each site during the repeated measurements, which were
made monthly. Because the threshold for what represented “true” attachment loss was set
reasonably high (i.e. >2.5 mm), continuous loss of attachment (e.g. increments of attachment loss
of say, 0.5 mm) could not be detected using these measurement and statistical approaches.
Further, the manner in which the Forsyth investigators calculated degrees of freedom and their
assumptions of the independence of the behaviour of individual sites within the same subject,
were not well-supported by conventional (parametric) statistical approaches based on Gaussian-
distributed data sets. Almost certainly, there are systemic factors in each subject that affect
multiple sites in a similar way (i.e. not all sites are indeed independent within the same subject).
Accordingly, considerable caution should be taken when considering the Forsyth model and its
relevance in understanding the natural history of periodontal disease progression.
In spite of our lack of understanding of how host immune responses regulate natural
history of periodontitis, there are reasonably good data to indicate that multiple modifying
factors can activate or inhibit the inflammatory response, and subsequently affect tissue
homeostasis and repair. Accordingly, it is anticipated that there will be wide variations of tissue
destruction both between and within patients over time if the host response varies. This
contention may explain the considerable variation that exists among individuals in terms of their
susceptibility to periodontitis, clinical manifestations, rate of disease progression and response to
treatment. One of the key cell types that play a crucial role in the inflammatory response and in
innate immunity is the neutrophil [43], [44].
7
2. Neutrophils
Neutrophils (polymorphonuclear leukocytes, PMN) are derived from the myeloid lineage
and represent the first line of defence against microorganisms [43], [45]. They originate from
multi-potential hematopoietic stem cells in bone marrow and differentiate in response to specific
growth factors [46]. Neutrophils are the most abundant and fastest migrating leukocytes, and are
crucially important cells of the innate immune system. Neutrophils are 12-15 µm in diameter
with abundant cytoplasmic granules and a segmented nucleus. Neutrophils can chemically sense
bacteria at a distance, move towards them, engulf and kill them [43], [45]. Although neutrophils
are a key requirement for mammalian survival, these same cells contribute to the pathogenesis of
several inflammatory diseases including inflammatory bowel disease [47], rheumatoid arthritis
[48] and periodontal diseases [49], [50].
a. Function
In response to bacterial stimulation [43] and to obtain access to the microbial “threat”,
neutrophils must exit the blood circulation between the intercellular junctions of small capillaries
and post-capillary venules. There are five sequential stages in the responses of neutrophils to
pathogens: (1) neutrophil rolling along capillary endothelium, (2) neutrophil adhesion to the
endothelium, (3) trans-endothelial migration, (4) chemotaxis, and (5) phagocytosis and
microbiocidal activity [51], [52], [53]. Neutrophil rolling and adhesion to endothelium is
mediated in part by a large number of adhesion molecules that include L-selectin [51], [53]. For
neutrophil adhesion to the endothelium, specific surface molecules arrest the rolling of
neutrophils, such as activated integrins located on the inflamed endothelial surface [54]. For
example, the beta 2 integrin (CD11/CD18), which is exclusively expressed by leukocytes,
modulates neutrophil adherence. Endothelial ICAM-1 (CD54) is its major ligand [54]. Although
8
ICAM-1 is constitutively expressed by endothelial cells, its expression levels are significantly
enhanced after stimulation with inflammatory mediators such as IL-1β, TNFα, INFγ or
endotoxin [55], [56].
Shortly after adherence to endothelium, neutrophils migrate between endothelial cells to
exit the vessel and reach the inflammatory site [57]. This process of neutrophil trans-endothelial
migration (diapedesis), unlike the previous stages, is not reversible. Two mechanisms have been
suggested that enable neutrophil trans-endothelial migration: (1) paracellular migration, which
involves squeezing of neutrophils between tight junctions that attach endothelial cells to one
another [58], [59] and, (2) Transcellular migration, a process by which neutrophils may migrate
through the individual endothelial cells via a transcytotic pathway [60]. The relative prevalence
of paracellular and transcellular migration is not yet defined in vivo.
Chemotactic migration of cells towards certain molecular gradients (e.g. chemotactic
factors) within the tissue is controlled by the organized development and disassembly of
adhesion complexes, which are tightly linked to actin filament assembly in the leading
lamellipodium of the cell [61]. Neutrophils migrate to the site of injury in response to
chemotactic factors that are receptor-dependent (e.g. IL-8, C5a, fMLP, substance P and platelet-
activating factor) or receptor-independent (e.g. phorbol esters) [62], [63]. Most in vitro studies of
neutrophil chemotaxis use the microbial peptide fMLP as a positive control. Chemokines are
small proteins that promote and guide migration of cells, mainly leukocytes, to the site of
inflammation [64]. Neutrophil responses to many chemokines involve hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2), which will then lead to a wide variety of important
signalling events that include synthesis of inositol triphosphate (IP3), mobilization of Ca2+
[65]
and tyrosine phosphorylation of a large array of adhesion-associated proteins [66], [67], [68].
9
At the site of injury, neutrophils recognize pathogens by means of opsonins, which
include either C3b complement fragments or antibodies specific to that pathogen. This
recognition process is followed by internalization of the bacteria and formation of the
phagosome [45], [69], [70]. After the internalization phase of phagocytosis, there are 2
microbiocidal pathways by which the phagocytosed pathogens are killed: (1) oxidative and (2)
non-oxidative pathways. The oxidative pathway is characterized by the respiratory burst that is
initiated by activation of NADPH oxidase. This process results in generation of superoxides,
hydrogen peroxide, hydroxyl radicals, hypochlorous acid and chloramines [71], [72]. The major
components of the non-oxidative pathway are the hydrolase granules within the neutrophils that
can degrade phagocytosed bacteria [71]. Simultaneously, extracellular killing of bacteria can
occur via secretion of enzymes such as collagenase, elastase and free radicals [73]. The
extracellular pathway may be particularly important in host cell-mediated tissue destruction in
diseases such as periodontitis and rheumatoid arthritis [48], [73].
b. Role of neutrophils in periodontal diseases
Neutrophils are a key component of the host inflammatory response in most infectious
diseases, including periodontitis. Neutrophils are the most abundant host cell type in the gingival
crevice and represent the first line of defence against bacterial challenges [74]. Impaired
neutrophil function in diseases like Chediak Higashi syndrome (defective degranulation),
leukocyte adhesion deficiency and Wiskott Aldrich syndrome (impaired chemotaxis) can
increase susceptibility to infections, including in aggressive periodontitis [75].
After emigration from periodontal blood vessels, neutrophils reach their microbial targets
by migration through the collagen-rich extracellular matrix of the periodontium. This migration
through the lamina propria of the gingiva is facilitated by the release of collagenase (MMP-8)
10
from neutrophils, which degrades extracellular matrix collagen [44]. Other contents of
neutrophils, such as elastase and oxygen radicals, are released into the extracellular space to kill
the bacteria, but these molecules can also be destructive to periodontal tissues [76], [77]. If
neutrophil-mediated tissue destruction predominates over tissue repair, there will be net loss of
periodontium, which is seen in periodontitis. In this instance, neutrophils are recruited to
neutralize periodontal pathogens; however, at the same time they contribute to periodontal tissue
destruction because of their release of degradative molecules [44]. In comparison to healthy
subjects, patients with progressive periodontitis express higher levels of collagenase [50],
oxygen radicals [78] and β–glucuronidase, which are associated with increased extracellular
matrix degradation [79]. Further, neutrophil-mediated tissue destruction is associated with
localized aggressive periodontitis [80]. Accordingly, disproportionate accumulation and
activation of neutrophils within the periodontium, followed by their degranulation and release of
matrix degrading enzymes, can lead to tissue destruction. This destruction is thought to be
largely the result of the host immune response [50]. In the context of this thesis, elevated
production and release of chemokines such as IL-8 may be one of the key host mechanisms that
mediate recruitment of neutrophils into the inflamed periodontium.
3. Chemokines
a. Structure and nomenclature
As mentioned above, chemokines are low-molecular-weight proteins composed of 70-80
amino acids that can mediate chemotaxis in adjacent responsive cells [64]. Chemokines contain
cysteines at well-conserved positions. Depending on the spacing of the first two cysteine
residues, there are four subgroups of chemokines. C chemokines have only two cysteines while
CC, CXC and CX3C chemokines have four to six cysteines (Fig. 1) [81].
11
Figure 1 Schematic structure of different chemokine subgroups
For C chemokines, one cysteine is located at the N-terminal cysteine and the second
cysteine is located towards the C-terminal [64], [81]. Two chemokines have been identified in
this subgroup, XCL1 (lymphotactin-α) and XCL2 (lymphotactin-ß). Both of these molecules
induce migration of T-cell precursors to the thymus [82]. In CC chemokines, the two cysteines
are adjacent to each other. A well known chemokine from this sub-group is monocyte
chemoattractant protein-l (MCP-1), which is a powerful chemoattractant for monocytes and T-
lymphocytes [83]. In response to specific stimuli, many different cell types including monocytes,
fibroblasts, smooth muscle cells, endothelial and epithelial cells can secrete MCP-1 [84]. At least
one human mast cell line can express MCP-1 mRNA and protein [85].
The two N-terminal cysteines in CXC chemokines are separated by one amino acid (X).
Based on the presence of a specific amino acid sequence (glutamic acid-leucine-arginine; ELR)
before their first cysteine, CXC chemokines are further subdivided into ELR+ and ELR
-
categories [81]. ELR+ CXC chemokines stimulate the migration of neutrophils and exhibit strong
angiogenic activity [86], [87]. IL-8 is an example of an ELR+ CXC that induces neutrophil
12
chemotaxis [81]. Other CXC chemokines that lack the ELR motif tend to be chemotactic for T-
helper 1 (Th1) lymphocytes and natural killer cells [88], [89], [90]. CXC chemokines bind to
CXC chemokine receptors; seven have been identified so far and are designated as CXCR1-7
[91], [92].
CX3C chemokines are differentiated from the CXC subgroup by the presence of three
amino acids between their cysteines [81]. The only member of the CX3C subgroup that has been
defined so far is CX3CL1, also known as fractalkine. It exists in two forms, a secreted and a
membrane-bound form. It can function as both an adhesion molecule and as a chemoattractant
[93]. In its membrane-bound form fractalkine promotes retention of T-lymphocytes and
monocytes at inflamed sites [94]. The secreted form possesses chemotactic activity for T-
lymphocytes, monocytes and NK cells [93]. Recent studies have suggested important roles for
CX3CL1 and its receptor CX3CR1 in affecting inflammatory and neoplastic diseases of the
cardiovascular, pulmonary, hepatic, pancreatic, intestinal, renal and musculoskeletal systems
[95].
A new nomenclature system has been proposed for chemokines and their receptors [96],
[97]. In this system, chemokines are named based on their cysteine subgroup (C, CC, CXC,
CX3C) followed by “L” for “ligand”. The terminal number corresponds generally to the same
number used in the associated gene nomenclature. Because most chemokine receptors are
restricted to a single chemokine sub-class, the nomenclature system of chemokine receptors is
rooted by the chemokine sub-class specificity, followed by “R” for “receptor” and the number.
Based on this new system, IL-8 is now named CXCL8 [96], [97].
13
b. Biology of IL-8
Interleukin-8 (IL-8) is a pro-inflammatory cytokine that promotes neutrophil chemotaxis
[21] and was the first member of the chemokine family to be discovered [64]. The cDNA for IL-
8 encodes a precursor, 99 amino acid protein, which is then cleaved into a 72 or 77-residue
mature protein [98]. Further proteolytic processing of IL-8 at the NH2 terminus leads to the
formation of 69-, 70-, 71-, 72- and 77-amino acid proteins [99], [100], [101], [102]. The 77- and
72-amino acid forms of IL-8 are two major sub-types and there is a smaller, 69-amino acid
protein. Among the three forms, the 69-amino acid protein is the strongest chemoattractant for
neutrophils. The 77-amino acid form, quickly converts to 72-amino acid form in vivo [103]. X-
ray crystallography and nuclear magnetic resonance spectroscopy have demonstrated that at
concentrations >100 µM, IL-8 forms a homodimer with two identical subunits. However, at
nanomolar concentrations, which are closer to pathophysiological levels, IL-8 occurs mainly in a
monomeric form and which exhibits a maximal biological effect [104], [105], [106].
c. IL-8 production
IL-8 is produced by a variety of cells including leukocytes (neutrophils, monocytes, T-
lymphocytes and natural killer cells) as well as fibroblasts, endothelial and epithelial cells [64],
[107], [108], [109]. IL-8 synthesis can be stimulated by pro-inflammatory cytokines such as IL-1
and TNF-α [98], bacterial products like lipopolysaccharide [64] and viruses and viral products
[110], [111], [112], [113]. Among environmental factors, low oxygen tension can induce IL-8
production by activation of the transcription factors NF-κB and activator protein-1 [114], [115].
NF-κB is activated by reactive oxygen intermediates, which then lead to IL-8 gene transcription
[116]. In most cells, co-operative activation of NF-κB and activator protein-1 is required for
initiation of IL-8 gene transcription [107].
14
d. IL-8 receptors and function
CXCR1 and CXCR2 are the two distinct, high affinity membrane-bound receptors for IL-
8, and contain 350 and 360 amino acids respectively [117], [118]. They are comprised of seven,
trans-membrane domains that in turn are functionally coupled to G proteins at the COOH-
terminal portion and possibly the third intracellular loop [96], [119]. Differences in the structure
of the NH2-terminal seem to account for different binding specificities.
In addition to CXCL8 (IL-8), CXCR2 binds CXCL1, CXCL2, CXCL3, CXCL5, CXCL6,
and CXCL7 with high affinity, while CXCR1 binds to CXCL6 only and with a lower affinity
than CXCL8 [96]. After binding to ligand, the receptor becomes internalized, which is followed
by recycling and reappearance on the plasma membrane in about 60 minutes [120]. Activation of
G proteins subsequent to ligand binding results in the generation of active phosphatidylinositol
3-kinase-γ which in turn leads to generation of PIP3 [119], [121]. PIP3 triggers protein kinase B
and the activation of small GTPases, which induce directed cell migration [121]. Both PI3K-γ-
dependent and -independent pathways play a role in mediating chemokine-induced chemotaxis
[122], [123]. Using ICAM receptors to enhance adherence, neutrophils follow a concentration
gradient of IL-8 during their chemotaxis within the tissue [124]. Several IL-8 analogues have
been reported including NAP-2, GRO proteins (GROα, GROβ and GROγ) and an epithelial cell-
derived neutrophil-activating protein, ENA-78. They all belong to the CXC family and are
similar to IL-8 in that they promote neutrophil chemotaxis [125].
e. IL-8 in periodontitis
Interleukin-8 (IL-8) is present in gingival crevicular fluid [40], [126], [127], and IL-8
mRNA is expressed in inflamed gingiva [128], [129]. IL-8 function is particularly important in
facilitating the transmigration of neutrophils and their accumulation at the surface of sub-
15
gingival biofilms [130]. The level of IL-8 increases following plaque accumulation during
gingivitis [131]. Further, Porphyromonas gingivalis, a well-known periodontal pathogen,
enhances IL-8 expression by human gingival fibroblasts, which in turn results in increased
neutrophil chemotaxis [36]. Similar findings have been reported with Tannerella forsythia,
another periodontal pathogen [37]. Further, IL-8 levels in gingival crevicular fluid are positively
correlated with the number of periodontal pathogens [132] and may reflect the rapidity of
periodontal destruction [40]. Gingival crevicular fluid levels of IL-8 increase in periodontitis
lesions and decrease significantly after periodontal treatment [39], [133], [134],. Similarly, IL-8
levels in plasma are significantly decreased after periodontal scaling in subjects with
periodontitis [135].
Elevated IL-8 production by stimulated gingival fibroblasts may lead to maintenance of
gingival inflammation and promote continuous tissue destruction [136]. In this context and as
noted above, IL-8 is produced by various cell types, including gingival fibroblasts [137].
Together with its receptors, CXCR1 and CXCR2, IL-8 is present within gingival epithelium
[138]. The increased cellular expression of CD40 may contribute to IL-8 production by
stimulated gingival fibroblasts [133].
4. Fibroblasts
Fibroblasts, mast cells, macrophages and lymphocytes comprise the main cell populations
of gingival connective tissue [139]. In healthy periodontal tissues fibroblasts are the most
abundant cell type and make up 65% of the total cell population [139]. The main functions of
fibroblasts are the synthesis and remodelling of extracellular matrix molecules such as collagen,
fibronectin, hyaluronic acid, tenascin and thrombospondin. Fibroblasts also regulate collagen
degradation [140] and, in wound healing, fibroblasts make important contributions to this
16
process by virtue of their ability to degrade and phagocytose collagen [141], [142], [143]. In
pathological states, there may be imbalances between degradation and formation of extracellular
matrix by fibroblasts, which can contribute to tissue fibrosis [144].
Not only do fibroblasts secrete proteins like collagen, but in wound healing they also
contract the wound edges via traction, a process that is enhanced when fibroblasts express α-
smooth muscle actin (α-SMA). Indeed, under certain conditions, fibroblasts can differentiate into
myofibroblasts, cells that are rich in α-SMA and exhibit enhanced contractile capacity [145],
[146]. α-SMA is frequently expressed by fibroblasts from the periodontium [147], which appears
to enhance collagen remodelling by traction [141].
Fibroblasts and macrophages are the main sources of tissue inhibitors of matrix
metalloproteinases (TIMPs) as well as MMPs [29]. The signals received by these cells from their
surrounding environment will affect important biological outcomes in inflamed sites [148],
[149]. Thus in healthy periodontium, actively expressed genes in gingival fibroblasts include
various collagens and TIMPs while the genes coding for MMPs increase expression during
periodontitis [35], [149], [150], [151]. In response to bacterial lipopolysaccharides, human
gingival fibroblasts secrete inflammatory cytokines such as IL-1β, IL-1α and IL-6 [152]. Further,
fibroblasts are among the main producers of IL-8 within connective tissues [137], [153].
a. Intercellular adhesion
Early electron microscopic studies of human gingival biopsies showed intimate contact
between damaged gingival fibroblasts and lymphocytes, suggesting that lymphocytes sensitized
to bacterial plaque might exert a cytotoxic effect on human gingival fibroblasts [154]. Fibroblasts
can function as antigen-presenting cells within the connective tissue and interact with T-
lymphocytes [155], [156], [157]. Indeed, direct adhesion of activated lymphocytes to fibroblasts
17
has been reported [158]. Intercellular adhesion can be induced following pre-treatment of
fibroblasts with IFN-γ [159]. ICAM-1 and LFA-1 can mediate adhesive interactions between
fibroblasts and lymphocytes [160]. Further, adhesion of T lymphocytes to human gingival
fibroblasts is increased in the presence of inflammatory cytokines such as IL-1, IFN-γ and TNF-
α. Adhesion may be enhanced by a combination of ICAM-1/LFA-1, the CD44/hyaluronic acid
pathway and VLA integrins [161], [162], [163]. Co-culture of human gingival fibroblasts with
lymphoid cells induces the expression of IL-1β, IL-1α and IL-6 mRNA plus hyaluronic acid,
which may enhance direct interactions between the two cell types [162], [164]. Conceivably,
direct contact between fibroblasts and lymphocytes may not only stimulate the inflammatory
response but may also increase the production of extracellular matrix proteins by fibroblasts
[164]. Indeed, histological studies of fibrotic diseases and asthma demonstrated that fibroblasts
are frequently in close proximity to mast cells and that these interactions play an important role
in the fibrotic process [165], [166], [167].
5. Mast cells
a. Origin and physiology
Mast cells are of the myeloid lineage and are derived from CD34+ pluripotential
progenitor cells in bone marrow [168]. Mast cell differentiation occurs partially in the bone
marrow under the effect of specific growth factors, primarily stem cell factor (SCF).
Differentiation also occurs in the blood circulation, while final maturation takes place in
connective tissues [169], [170].
Mast cells are widely distributed throughout many connective tissues. As part of host
defence systems, mast cells are strategically located close to the surface epithelium for optimal
interaction with environmental triggers [168], [171]. Typically, there are ~20,000 mast cells/mm3
18
in the intestinal lamina propria and this cell density increases in response to inflammation [172].
In the oral cavity mast cells are found throughout the gingival connective tissue and are often in
close proximity to endothelial cells; but they can also be found within the epithelium [172],
[173]. Based on their proteinase content, mast cells are divided into two main groups. Those
mast cells that only contain tryptase and reside in mucosa are designated as MCT. Another type
of mast cell which contains both tryptase and chymase are found in connective tissue (MCTC)
[174].
b. Mast cell mediators
Mast cell tryptase is a tetrameric trypsin-like serine protease (molecular mass of 134
kDa) and is the major secretory component of human mast cells [175]. Tryptase is comprised of
four monomers, which are non-covalently bound together. The active sites of these monomers
face the central pore of the enzyme molecule [176]. α-tryptase and β-tryptase are the two main
types of mast cell tryptases, which are further divided into α1, 2 and βI, II and III subtypes
respectively [177], [178]. Tryptase is stabilized by heparin, which prevents it from being
converted to inactive monomers. β-tryptase substrates include fibronectin [179], fibrinogen
[180], pro-urokinase [181], pro-matrix metalloprotease-3 (proMMP-3) [182], protease -activated
receptor-2 [183] and complement component C3 [184].
MCTC mast cells produce and secrete chymase, which is a chymotrypsin-like protease
[185]. Chymase converts angiotensin I to angiotensin II [186], cleaves type I pro-collagen to
collagen fibrils [187] and digests several cytokines [188]. Histamine is a very well-known mast
cell mediator and is primarily secreted during immune responses such as allergy. Histamine
plays a variety of roles including vasodilation, bronchoconstriction and increased vascular
permeability [189]. Histamine is stored in granules (100 mM concentration) [190], [191]. After
19
release, histamine is rapidly catabolised by oxidation and methylation. Four histamine receptors
have been identified so far: HR1, HR2, HR3 and HR4 [189].
Heparin and chondroitin sulfate are two of the most abundant proteoglycans found in
mast cells. These molecules function as stabilizers for some other pre-formed mediators,
including proteinases. Further, they possess anti-coagulant and anti-complement effects [191].
Mast cells also contain metabolites of both cyclooxygenase and lipooxygenase pathways
including prostaglandins (PG), thromboxanes (TX), leukotrienes (LT) and 5-, 12-HETEs
(hydroxy-eicosatetraenoic acids). PGD2, LTB4 and LTC4 are among the most abundant lipid-
derived mediators in mast cells [191].
As noted above, matrix metalloproteinases are among the host-related molecules that are
associated with rapid tissue destruction in periodontal tissues. MMP-1 is present in gingival mast
cells [192] and mast cells also produce MMP-1 and MMP-8 (about half of mast cells can express
MMP-2 and TIMP-1). Only a small fraction of mast cells express TIMP-2 [192], [193]. These
findings suggest that mast cells should be considered as important cells in mediating the host-
response in periodontitis.
In addition to the molecules described above, mast cells can produce and release a large
number of cytokines including IL-1β, -3, -4, -5, -6, -8, -10, -12 (only the p35 chain),-13, -16,
TNF-α, GM-CSF, TGF-β, IFN-γ and VEGF [194], [195]. The level of maturation affects the
ability of mast cells to synthesize cytokines (Fig. 2) [196].
20
Figure 2 Mast cell mediators are stored in a pre-formed state* or may be newly generated in response to stimuli
[196].
c. Mast cell proliferation and activation
As described above, mast cells differentiate from bone marrow-derived, hematopoietic
progenitors. The exact mechanism by which these cells exit the bone marrow and migrate to
connective tissues is not fully understood, but earlier studies showed that P-selectin may play a
role in the initial migration of mast cells from the bone marrow [197]. Adhesion molecules are
believed to be important in localization and accumulation of mast cells within tissues [198].
Some of the surface adhesion molecules that have been identified in mast cells include integrins
such as VLA-3, VLA-4 and VLA-5, suggesting that mast cell localization to connective tissues
may require interactions with collagen, fibronectin and laminin [199], [200].
In the context of chemokine receptors, immature mast cells express CXCR2, CXCR4,
CCR3 and CCR5. But after reaching maturity, mast cells only express CCR3 [201]. The c-kit
ligand stem cell factor (SCF) induces mast cell proliferation both in vitro and in vivo [202],
[203], [204]. The SCF effect is augmented in the presence of IL-3 [205]. Mast cells undergo
apoptosis after withdrawal of IL-3, but this process can be prevented if cells are treated with SCF
[206], [207]. IL-4 also promotes mast cell proliferation and may function synergistically with IL-
21
3 [208], [209]. Other activators of mast cells include complement fragments C3a, C4a and C5a,
which induce degranulation and anaphylactoid reactions [210], [211].
d. Immune function
Mast cells express surface receptors for the Fc portion of IgE (FcεRI) and play a role in
IgE-associated immune responses such as type I hypersensitivity. However, mast cells can
become activated and exert their immunomodulatory functions through other IgE-independent
mechanisms [212], [213], [214]. Mast cells are capable of phagocytosis and can function as
antigen-presenting cells [215], [196] and contribute to wound healing [194]. Recent studies have
suggested a role for mast cells in the pathophysiology of chronic inflammatory disorders such as
cardiovascular diseases and atherosclerosis through their impact on regulating lymphocyte and
macrophage function [216], [217], [218].
Mast cell populations increase during the development of periodontitis and in sites with
progressive attachment loss [219], [220], [221], [222]. On the other hand, not all the functions of
mast cells are pro-inflammatory. Despite the fact that mast cells are key cells in IgE-associated
immune responses such as asthma, β-tryptase, which is a mast cell protease, is able to cleave IgE.
Conceivably, this process may limit the allergic response. This contention has been supported by
the finding of IgE degradation products in allergic inflammatory sites [223]. Further, mast cells
produce IL-10, which is an anti-inflammatory cytokine and limits leukocytic infiltration [224].
e. Angiogenesis
Mast cells are in close proximity to blood vessels of connective tissues [225], [226].
Activation of mast cells in adult mammalian tissues can induce angiogenesis [227], [228]. Mast
cell secretions increase vascularity by stimulating the proliferation of endothelial cells and their
migration [229], [230]. Angiogenesis in mast cell-deficient animals occurs at a reduced rate but
22
is restored by local reconstitution of mast cells [231]. Among mast cell mediators, histamine has
the most potent angiogenic effect [228] while TNF-α has both stimulatory and inhibitory effects
[232]. Heparin potentiates the effect of fibroblast growth factor, a key angiogenic factor, perhaps
by increasing its affinity to its receptors [233]. Further, mast cells can degrade extracellular
matrix to provide space for newly formed vessels [233]. During wound healing fibroblast growth
factor, VEGF and PDGF promote mast cell chemotaxis to sites of neovascularisation [234].
f. Mast cells and T-lymphocytes
By electron microscopy, direct intercellular adhesion between mast cells and T-cells has
been shown; this is a key requirement for antigen-presenting functions [235]. Mast cells produce
and secrete the CXC chemokine IL-8, which is a potent chemokine for both neutrophils and
lymphocytes [236], [237], [238]. Further, mast cells secrete lymphotactin and IL-16, which are
chemotactic factors for CD8+ and CD4
+ lymphocytes respectively [239], [240]. Mast cell
expression of macrophage inflammatory protein (MIP)-1β positively affects T-cell emigration
from the circulation into lymph nodes during the inflammatory response [241]. In addition to
attracting lymphocytes, mast cells can migrate towards these cells by means of integrins [241],
[242],[243]. A list of mast cell receptors is shown in Figure 3.
Figure 3 Mast cell surface receptors [196]
23
g. Mast cells and fibroblasts
Previous histological studies have shown that fibroblasts are frequently in close
proximity to mast cells and that their interactions may be important for many cellular processes
[165], [166], [167]. Studies of fibrosis have suggested the possibility that gap junctions can form
between these two cell types [244], [245]. Fibroblasts produce and secrete stem cell factor
(SCF), the ligand of the c-kit proto-oncogene product, which is a major regulator of human mast
cells and promotes their proliferation and differentiation. SCF enhances mast cell maturation and
directly stimulates release of mast cells mediators such as histamine [246]. Fibroblast-derived
SCF also upregulates the expression of MCP-1 and eotaxin (a potent eosinophil specific C-C
chemokine) in mast cells [247], [248].
Conversely, mast cells also affect fibroblasts in multiple processes. The expression of
SCF by fibroblasts, which can activate mast cells, is upregulated in response to TNF-α, a mast
cell mediator [249]. Tryptase promotes fibrosis by stimulating human fibroblast chemotaxis
[250] and by increasing collagen synthesis [165], [251]. Tryptase also induces the proliferation
of fibroblasts via protease-activated receptor-2 signalling, which may account for the hyperplasia
seen in asthma [251], [252]. Collagen gel contraction studies have shown that in co-culture, mast
cells increase fibroblast contractility and may induce their differentiation into myofibroblasts
[253], [254], [255], [256].
Mast cells express fibroblast growth factor-2 (FGF-2) and are able to stimulate FGF-2
secretion (via tryptase) and FGF-7 secretion (via histamine) by human fibroblasts [257]. Mast
cells and their products can also promote the expression of inflammatory cytokines by
fibroblasts. Tryptase can enhance expression of IL-8 in synovial fibroblast-like cells and also
induce their proliferation [258]. Interactions between human lung fibroblasts and mast cells,
24
which were studied in co-culture, showed that mast cells induce IL-6 expression by fibroblasts
[166]. Studies of lung fibroblasts demonstrated that CD40, a membrane glycoprotein, is a crucial
factor in fibroblast activation by mast cells [259]. Expression of CD40 has been reported in
human gingival fibroblasts [260]. Ligation of CD40 receptors promotes synthesis of
inflammatory cytokines such as IL-1, IL-6, IL-8, PGs and hyaluronate (an ECM protein) [260],
[261], [262]. Several cell types including mast cells express CD40 ligand (CD40L) [259].
Therefore, hypothetically, mast cells may potentially activate fibroblastic CD40 receptors and
cause an increase in inflammatory cytokine production. Evidently, mast cells may collaborate
with fibroblasts in a wide range of metabolic activities. These findings underline their potentially
interactive roles in connective tissue remodelling in inflammatory diseases such as periodontitis.
25
Statement of the problem:
Periodontitis is the second most prevalent infectious disease of North Americans and affects
>30% of the US adult population [3]. Periodontitis is associated with increased risk of various
systemic diseases including diabetes, myocardial infarction and stroke [5], [7]. Host responses to
periodontal pathogens contribute to the pathogenesis of inflammatory systemic diseases and play
a central role in the progression of periodontitis [26], [27], [263]. Due to our lack of knowledge
of how host response mechanisms control episodic exacerbations in periodontitis [42], current
clinical management of periodontitis cannot always be optimized to improve the clinical course.
Neutrophils are critical cells in the innate immune response and are the first line of defence
against periodontal pathogens [74]. Neutrophils release proteolytic enzymes, which mediate
periodontal tissue destruction in acute inflammatory episodes [50]. Neutrophil chemotaxis into
inflamed sites is promoted by interleukin-8 (IL-8; or CXCL-8) [21], [40],[126], a pro-
inflammatory chemokine. IL-8 is expressed by several cell types including gingival fibroblasts
[137]. IL-8 levels in gingival crevicular fluid are increased in periodontitis and are reduced after
periodontal treatment [133], [134].
Fibroblasts are the most abundant cells of gingival connective tissue and contribute to the
synthesis and degradation of periodontal extracellular matrices [264]. Fibroblasts are often
located in close proximity to inflammatory cells, including mast cells. Indeed, their interactions
with mast cells and other immune cells may be important for intercellular signal transduction
pathways that mediate the host response [162], [164], [165], [166], [167]. Mast cells are of the
myeloid series and are normal residents of periodontal connective tissues. The abundance of
mast cells increases during periodontitis and in sites with progressive attachment loss [219],
26
[220], [221], [222]. Notably, fibroblasts form gap junctions with mast cells in fibrotic lesions
[244], [245] but it is not known whether direct interactions between mast cells and fibroblasts
affect fundamental regulation of the inflammatory response.
Hypothesis: Mast cells interact with fibroblasts to regulate IL-8 release and perpetuation of
inflammation.
Objectives:
1) Measure IL-8 levels in co-cultures of fibroblasts with mast cells.
2) Study fibroblast-mast cell co-cultures to assess their impact on neutrophil chemotaxis.
3) Examine intercellular communication between fibroblasts and mast cells.
4) Identify molecules that mediate IL-8 production in fibroblast-mast cell co-cultures.
27
Chapter 2: Role of intercellular interactions between mast cells and gingival
fibroblasts in mediating inflammation
Introduction
Periodontitis is a chronic inflammatory disease that is characterized by recurrent episodes
of acute exacerbation and increased destruction of bone and soft connective tissues [42]. While
the mechanisms that initiate these acute exacerbations are not defined, host immune responses to
the pathogenic microbiota that colonize the periodontium likely contribute to tissue destruction
[263]. Neutrophils are key components of the inflammatory response and are the most abundant
cell type in the gingival crevice, where they are the first line of defence against colonizing
bacteria [74]. Degranulation and release of matrix-degrading enzymes from neutrophils can lead
to excessive tissue destruction in acute exacerbations of periodontitis [50]. Notably, neutrophil
migration into inflammatory sites is induced by chemokines [61]. One of the most potent
chemokines that promotes neutrophil chemotaxis is interleukin-8 (CXCL-8) [21]. The levels of
IL-8 in gingival crevicular fluid are temporally related to periods of periodontal destruction [40],
[126] and are decreased after treatment [133], [134]. IL-8 is produced by various cell types
within the periodontium, including gingival fibroblasts [137].
Fibroblasts are the most abundant cells of gingival connective tissue and play key roles in
the synthesis, degradation and remodelling of the extracellular matrix of the periodontium [264].
Gingival fibroblasts (HGF) also contribute to the control of inflammation by secretion of
inflammatory mediators such as IL-1β, IL-1α, IL-6 and IL-8 [137], [152], [153]. Notably,
fibroblasts interact with immune cells including lymphocytes and mast cells. Co-culture of
28
human gingival fibroblasts with T-lymphocytes induces the expression of inflammatory
cytokines by fibroblasts as a result of direct interactions between these two cell types [164].
Further, fibroblasts are frequently in close proximity to mast cells in vivo [165], [166], [167].
Mast cells, which are of the myeloid lineage, are normal residents of periodontal
connective tissues. The numbers of mast cells increases during periodontitis and at sites with
progressive attachment loss [219], [220], [221], [222]. Mast cells and fibroblasts can interact to
form gap junctions [244], [245], which may be important in the development of fibrosis. Direct
interactions between mast cells and lung fibroblasts can enhance the expression of IL-6 [166]. As
IL-8 is produced by gingival fibroblasts [137], we examined interactions between mast cells and
gingival fibroblasts to define their potential effects in regulating acute inflammatory response
through IL-8 release.
29
Materials and methods
Reagents
Alpha-thioglycerol, β-glycyrrhetinic acid (BGA), bovine serum albumin (BSA), brefeldin A
(BFA), fMLP, HEPES, Percoll, protease inhibitor cocktail, rhodamine B isothiocyanate dextran
(10 kDa) and thapsigargin (TSGN) were purchased from Sigma-Aldrich (Oakville, ON).
Ionomycin was from Calbiochem-EMD (Mississauaga, ON). Calcein-AM and FITC-dextran
(70 kDa) were obtained from Molecular Probes (Eugene, OR). HBSS, α-MEM and IMDM were
purchased from GIBCO®
, Invitrogen (Burlington, ON). Purified bovine collagen solution was
obtained from PureCol®,
Advanced BioMatrix Inc. (San Diego, CA). The 4B4 IgG1 monoclonal
antibody was purchased from Beckman Coulter (Mississauga, Ontario). The 2-µm diameter
polystyrene and protein-A conjugated microspheres were obtained from Polybead®, Polysciences
Inc. (Warrington, PA). E-Lyse was purchased from Cardinal Associates (Phoenix, AZ). Normal
mouse serum and human cytokine antibody array #5 were obtained from Cedarlane (Burlington,
ON). Human CXCL8/IL-8 QuantiGlo ELISA kits were purchased from R&D Systems
(Minneapolis, MN).
Cell Cultures
Human gingival fibroblasts (HGF) were derived from primary explant cultures as described
[265]. Cells from passages 4–10 were grown as monolayers in T-75 flasks. Full growth medium
consisted of α-minimal essential medium (α-MEM), antibiotics (0.017% v/v penicillin G; Ayerst,
Montreal, Canada; 0.01% v/v gentamycin sulfate in α-MEM) and 10% (v/v) heat-inactivated
fetal bovine serum (ICN Biomedicals, Costa Mesa, CA). The cells were grown to 80-100%
confluence prior to all experiments. Fibroblasts were passaged with 0.01% trypsin.
30
The human mast cell line (HMC-1) was kindly provided by Dr. J.H. Butterfield (Mayo Clinic,
NY). Mast cells were grown in suspensions in T-75 flasks according to a previously described
protocol [266]. Mast cell growth media contained Iscove's modified Dulbecco's medium
(IMDM) supplemented with 1.2 mM alpha-thioglycerol, 10% (v/v) heat-inactivated calf serum,
100 U/ml penicillin and 100 U/ml streptomycin. For passaging, cell suspensions were
centrifuged for 8 minutes at 400xg. Both types of cells were grown at 37ºC in a humidified
incubator containing 5% CO2 and were counted electronically (Beckman Coulter).
Cytokine array
Fibroblasts were grown on 6-well cell culture plates (Falcon, Becton Dickinson, Mississauga,
ON). When 80% confluent (200,000 cells per well), growth media were replaced with serum-free
α-MEM. For co-cultures, 100,000 mast cells were incubated on monolayers of fibroblasts at a
1:2 ratio. Conditioned media from these co-cultures or from cultures of fibroblasts or HMC alone
were collected after 8 hours. Cytokine expression was analyzed with a human cytokine antibody
(array #5; RayBiotech, Inc) according to the manufacturer’s instructions. Briefly, each cytokine
array membrane was incubated with blocking buffer at room temperature for 30 minutes and
then incubated overnight with 1 ml of conditioned media at 4°C. After washing, the membranes
were incubated with primary antibody for 1.5 hours at room temperature followed by another
wash and incubation with HRP-conjugated streptavidin secondary antibody for 2 hours at room
temperature. After the final wash, detection buffer was applied on membranes for 2 minutes and
arrays were exposed to x-ray film (Kodak, Canada).
IL-8 quantification
HGFs were grown on 6-well plates to reach 80% confluence (200,000 cells/well). Growth media
were replaced with serum-free α-MEM unless otherwise indicated and HMC-1 cells were added
31
at a 1:2 ratio (100,000 mast cells per well). HGFs were co-cultured with HMC-1 cells for 8 hours
except for time-course experiments, which were performed from 1-8 hours both in the presence
and absence of serum. Pure cultures of either HGF or HMC-1 were used as controls. For
examination of dose-response effects, fixed ratios of HGF:HMC (2:1, 1:1, 1:2, 1:4) were
examined after 8 hours. Following co-incubation, supernatants were collected, samples were
sedimented (5 minutes at 9300xg) to remove particulates from the conditioned medium, and the
media were stored at -20ºC for later quantification of IL-8 by ELISA.
For IL-8 quantification, human CXCL8/IL-8 QuantiGlo ELISA kits (R&D Systems,
Minneapolis, MN) were used. Briefly, previously stored samples were thawed at room
temperature and 50 µl samples were loaded into each well of 96-well IL-8 ELISA plates.
Following 2 hour incubations at room temperature on a shaker, wells were aspirated and washed
four times with wash buffer (400 µL), incubated with 200 µl of IL-8 antibody conjugate,
incubated for 3 hours at room temperature, washed and incubated with 100 µl of Working Glo
Reagent for 5 - 20 minutes at room temperature while being protected from light. The relative
luminescence of each well was measured with a luminometer (FLUOstar OPTIMA, BMG
Labtech, Germany). The average of duplicate readings was collected and the concentration of IL-
8 was estimated from a standard curve of known IL-8 concentrations.
Integrin and cadherin ligation
We determined whether co-culture-mediated IL-8 release involves adhesion molecules. HGFs
were incubated with either BSA or type I bovine dermal collagen [267] or N-cadherin [268] -
coated 2-µm polystyrene beads. The N-cadherin-Fc fusion protein was expressed in HEK-293
cells and collected as described [269]. Beads were counted with a hemocytometer.
32
The effect of BSA-coated beads on IL-8 expression was compared to mast cells. In this
experiment 50,000 HGFs at 100% confluence on 24-well cell culture plates (Falcon) were co-
incubated with either 50,000 BSA-coated latex beads or 50,000 HMCs in serum containing
fibroblast growth media. Samples of conditioned media were collected at 0, 1, 2 and 4 hours.
For comparison of the effect of ligation of adhesion receptors, 40,000 HGF were grown on 24-
well plates and were incubated for 4 hours with either BSA-coated, collagen-coated or N-cad-Fc
protein-coated beads. For each condition, 240,000 beads were incubated with cells at a 1:6 ratio
of HGF:Beads. For comparison, co-cultures of HGF:HMC and HGF:HGF (both at 1:1 ratios)
were established. Conditioned media was collected after 4 hours. Samples were prepared, stored
and IL-8 was quantified by ELISA.
Intercellular contact and IL-8 expression
We assessed the importance of direct cell-cell contact on IL-8 release from fibroblasts. HGFs
were grown on 6-well plates as described above (200,000 cells per plate) and then 100,000 mast
cells were plated on 25 mm diameter Cyclopore® membranes (Whatman Inc, NJ; pore size-0.45
µm) which were inserted into the fibroblast cultures. This approach physically separated the mast
cells from HGFs during co-culture but allowed free passage of small molecules to exchange
between fibroblasts and mast cells (Fig. 4).
In a separate experimental approach, the effect of mast cell sonicates on HGFs was
examined. Mast cell suspensions in αMEM were sonicated (Branson model 185; 5 times for 10
seconds each; output setting of 5.0) on ice in the presence of protease inhibitors. A volume of
sonicate from 100,000 HMC was added into each well of a 6-well plate containing HGFs.
Following incubation at 37ºC for 8 hours, IL-8 levels were measured.
33
Figure 4 Cyclopore®
membrane physically separated HMC from HGF preventing them from establishing direct
contact
We examined a possible role for gap junctions in IL-8 release. HMCs and HGFs were pre-
incubated with the gap junction inhibitor, β-glycyrrhetinic acid (BGA; 100 µM; Sigma-Aldrich,
ON) for 1 hour. Cells were co-cultured at a 2:1 ratio (HGF:HMC). BGA was present throughout
the 8-hour co-incubation period. Samples were collected at 8 hours for quantification of IL-8.
Flow cytometry was performed to quantify the effect of BGA on gap junction formation. HMC-1
(donor) cells were incubated with calcein/AM (5 µg/ml) for 1 hour at 37ºC. HGFs and HMCs
were treated with 20 µM BGA for 1 hour and were then co-cultured in the presence or absence
of BGA. After 1 and 3 hours, media were aspirated and co-cultures were rinsed with PBS to
remove unbound HMCs. Cells were detached from culture plates with 0.01% trypsin. After
sedimentation, cells were re-suspended in PBS and analyzed by flow cytometry (Beckman
Coulter Altra, Mississauga, ON). Laser excitation was 488 nm. To minimize measurement of
fluorescence attributable to HMCs, side and forward scatter gates were set to maximize
measurement of HGFs. Calcein fluorescence was measured in 10,000 HGFs in each samples
from BGA and control groups after 1 and 3 hours of co-culture. In some experiments, since cold
34
temperature inhibits gap junction formation in vitro [270], co-cultures were conducted at 4ºC in
α-MEM and supplemented with 25 mM HEPES buffer to stabilize the pH.
IL8 secretion
We determined whether changes of IL-8 levels were due to protein secretion. Cells were treated
with the protein secretion inhibitor, brefeldin A (BFA) at 10 µg/ml for 30 minutes prior to co-
culture. BFA was present throughout the co-culture period. Samples were collected after 8 hours
of co-culture for IL-8 quantification.
Role of calcium
As calcium is an important second messenger that may be involved in intercellular signalling
events between fibroblasts and mast cells, in some experiments we stimulated cells with
thapsigargin (TSGN), a sesquiterpene lactone that inhibits Ca2+
uptake by the endoplasmic
reticulum and causes a net increase of intracellular free ionic calcium levels [Ca2+
]i. In other
experiments we used ionomycin, a calcium ionophore, to increase [Ca2+
]i. HGFs were grown on
6-well plates as described above and pure cultures of either HGFs or HMCs were treated with
TSGN (500 nM) for 30 minutes prior to co-culture. Treated cells were rinsed twice with
phosphate buffered saline (PBS) to remove any remaining TSGN prior to co-culture
(HGF:HMC=2:1) for 8 hours. For experiments using ionomycin, both cell populations were
incubated with ionomycin (2 µM) 30 minutes prior to co-culture. HMCs were added to HGF,
similar to the TSGN experiment except that ionomycin was present throughout the 8 hour co-
culture period.
Neutrophil chemotaxis
We examined the effect of co-culture conditioned medium on neutrophil chemotaxis. Mouse
neutrophils were isolated as previously described [271]. Briefly, following euthanasia, femurs
35
and tibias were removed and bone marrow was isolated. After lysing erythrocytes (E-Lyse),
discontinuous Percoll gradients of 82%/65%/55% were used to layer the remaining bone marrow
[271]. Mature neutrophils were recovered at the 82%/65% interface. Wright-Giemsa staining has
identified over 85% of cells isolated using this protocol as neutrophils [272]. For analysis of
chemotaxis, neutrophils were suspended in HBSS and 1% gelatine and this suspension (1 x
106/ml) was allowed to attach to BSA-coated glass coverslips (22
x 40 mm) at 37°C for 20
minutes. Coverslips were inverted on to Zigmond chambers and 100 µL HBSS media was added
to the left chamber with 100 µL HBSS media containing fMLP [10
-6] as positive control.
Samples of conditioned media were added to the right chamber. Time-lapse video microscopy
was used to quantify neutrophil migration. Images were
captured at 20-second intervals with a
Nikon Eclipse E1000 microscope. Cell-tracking software (Retrac version 2.1.01 Freeware) was
used to analyse the captured images and to measure the speed and distance travelled by
neutrophils [272]. All procedures were conducted in accordance with the Guide for the Humane
Use and Care of Laboratory Animals and this protocol had been approved by the University of
Toronto Animal Care Committee.
Microscopy
We observed the spatial relationship between mast cells and fibroblasts by phase contrast light
microscopy. HGFs were grown on 35-mm-diameter culture dishes (Falcon, Becton Dickinson,
Mississauga, ON) in HGF growth media. At 80% confluence, mast cells were added
(HMC:HGF=2:1 ratio). Following 24 hours of co-culture, medium was aspirated and cultures
were jet-washed [273] with phosphate buffered saline (PBS) to remove unbound or loosely
attached cells. A light microscope (Leitz Wetzlar, Germany) and camera (PixeLINK PL-A642)
were used to obtained images of the attached cells.
36
Intercellular adhesion
To study intercellular communications between mast cells and gingival fibroblasts in our
simplified model [274], HGF were grown overnight to 80% confluence in normal growth media.
HMC-1 (donor cells) were fluorescence-labeled with calcein-AM (5 µg/ml) for 1h at 37°C,
followed by three washes with α-MEM. These cells were then plated onto the established HGF
monolayer (acceptor cells). Cells were co-cultured in HGF growth media supplemented with 25
mM HEPES to stabilize pH. Dye transfer from HMC-1 (donor) into HGF (acceptor) was
monitored via live imaging (0–360 min) and recorded at specific time points with a laser-
scanning confocal microscopy (Leica TCS SL, Heidelberg, Germany). Calcein was imaged with
excitation set at 488 nm and emission was collected with a 530/20-nm barrier filter. Cells were
imaged with a 40x 1.25 oil-immersion lens. Transverse optical sections were obtained from the
level of cell attachment at the substratum of the acceptor cell to the dorsal surface of the donor
cell (as verified by phase-contrast microscopy).
Role of integrins in HGF-HMC attachment
HGFs (15,000) were grown on 8-well chamber slides (Falcon, Becton Dickinson, Mississauga,
ON). HGFs and HMC cultures were incubated separately overnight at 37ºC with 2 mg/ml FITC
Dextran and 1 mg/ml Rhodamine B isothiocyanate dextran respectively. The next day, HGFs
were rinsed twice with PBS. Growth medium containing an attachment inhibitory antibody
against β1 integrins (4B4 at 1:20 dilution) was added to wells (15 µl of 4B4 mAb in 300 µl of
growth media per chamber). For controls, normal mouse serum at 1:100 dilution was used
instead of 4B4. After incubation for 1 hour, 7500 mast cells were added on to HGFs. Chamber
slides were rinsed with PBS at 1, 3 and 6 hours following co-culture in all three groups and the
37
ratio of attached HMC to HGF was calculated by counting the cells under the fluorescent
microscope (Leica, Heidelberg, Germany) using FITC and RITC filters.
Statistical Analysis
For cell culture experiments, biological triplicates and technical duplicates were used. Means
between 2 groups were compared using the unpaired Student’s t-test. p<0.05 was considered to
be statistically significant.
38
Results
We used an antibody array to assess the release of inflammatory cytokines into the medium after
co-culture of fibroblasts with mast cells. After 8 hours of fibroblast-mast cell co-culture there
were increased levels of several inflammatory cytokines including IL-8, GRO (IL-8-related
chemokine), IL-6 and MCP-1 (CCL2) compared to control fibroblasts, which were cultured in
the absence of mast cells (Fig. 5A). Based on previous reports showing enhanced IL-8 release in
response to ligation of CD40 on fibroblasts by the CD40 ligand that is also expressed by mast
cells [259], [260], [262] and because of the importance of IL-8 in promoting neutrophil
recruitment to inflammatory sites [43], we focussed subsequent investigations on IL-8.
Effect of fibroblast-mast cell co-culture on IL-8
We quantified IL-8 levels in serum-free media of fibroblast-mast cell co-cultures using an
ELISA. In initial experiments that examined cells after 8 hours of co-culture, there were
significantly increased IL-8 levels (p<0.001) in conditioned media compared to fibroblasts plated
alone (Fig. 5B). While fibroblasts alone secreted measurable levels of IL-8, the amount of IL-8
secreted by mast cells was negligible (0.02±0.01 pg/ml).
We determined whether there was a dose-response effect between the relative numbers of
mast cells and levels of IL-8 by adjusting the ratios of mast cells to fibroblasts in co-cultures.
The levels of IL-8 were increased 30-fold when the ratios of mast cells to fibroblast were
increased 8-fold (from 1:2 to 4:1; Fig. 5C; p<0.001).
We assessed whether there was a time-dependent increase of co-culture-induced IL-8.
Within 2 hours there was a statistically significant difference between fibroblasts alone and
fibroblasts cultured with mast cells (p<0.05; Fig. 5D) and by 8 hours there was 50% more IL-8 in
the co-cultures than fibroblasts alone.
39
We determined whether the stimulatory effect of co-culture on IL-8 release was affected
by serum. In comparison to serum-free conditions, co-culture of cells in the presence of serum
showed 50-fold higher levels of IL-8 and in mast cell-fibroblast co-cultures compared to
fibroblasts alone, IL-8 levels were >40-fold higher (Fig. 5E).
Role of adhesion molecules
We examined whether co-culture-driven increases of IL-8 were mediated by ligation of specific
adhesion molecules expressed by fibroblasts. HGFs were incubated with collagen or N-cadherin-
coated beads in serum-containing medium; BSA-coated beads were used as controls and IL-8
was measured after 0-4 hours. In contrast to time-dependent increases of IL-8 in mast cell-
fibroblast co-cultures, incubation of fibroblasts with BSA-coated beads did not significantly
increase IL-8 levels (Fig. 6A). Similarly, there were no increases of IL-8 levels when HGFs were
incubated with N-cadherin or collagen-coated beads (Fig. 6B). Further, we incubated single cell
suspensions of fibroblasts on to previously spread, homotypic fibroblast monolayers and found
that after 4 hours there were no statistically significant differences of IL-8 levels in conditioned
media between homotypic fibroblast co-cultures and fibroblast monolayer cultures (p>0.05).
Intercellular adhesion
The effect of serum on co-culture-mediated-IL-8 release suggested that attachment and spreading
of mast cells on to fibroblasts may be important for the enhanced IL-8 release. We assessed
intercellular adhesion between fibroblasts and mast cells after 24 hours of co-culture in serum-
containing media by light microscopy, which showed that even after vigorous rinsing with PBS
(Fig. 7 A,B), large numbers of mast cells remained attached to the fibroblasts. Notably, as mast
cells normally grow in suspension and do not tend to adhere to plastic culture surfaces [266], we
40
considered that mast cell attachment to fibroblasts and the potential transfer of intercellular
signals may be important for the induction of IL-8 release.
Role of integrins
In separate culture containers, fibroblasts and mast cells were loaded overnight with FITC-
dextran and rhodamine B isothiocyanate dextran, respectively, a procedure [274] that selectively
marks these two cell populations. On the next day, fibroblasts were pre-treated with a β1 integrin
blocking antibody (4B4) or control IgG and then mast cells were added to fibroblast monolayer
cultures. The ratios of the numbers of attached mast cells to fibroblasts were determined at 1, 3
and 6 hours after incubation by enumerating the two, differentially labelled populations by
fluorescence microscopy (Fig. 7C). For all three time points, pre-treatment with the β1 integrin
inhibitory antibody significantly reduced the ratio of attached mast cells to fibroblasts (p<0.001).
We studied intercellular communication between mast cells and fibroblasts by loading
mast cells with FITC-calcein/AM, a small (MW=995 Da) fluorescent molecule that exchanges
between attached cells through gap junctions [275]. Calcein-loaded mast cells were incubated on
unstained fibroblasts, confocal imaging was performed and images were recorded every 30
minutes for six hours. Within 60 minutes of co-incubation, there was detectable dye transfer
from mast cells to the fibroblasts, which increased over prolonged incubation (Fig. 7D).
We examined the role of gap junctions by pre-treatment of cells with the gap junction
inhibitor, BGA. At defined periods after co-cultures were started, single cell suspensions were
prepared and flow cytometry was used to quantify the relative number of fibroblasts that
exhibited above-threshold calcein fluorescence. Forward and side scatter were used to
distinguish fibroblasts from mast cells. BGA reduced calcein fluorescence in fibroblasts
41
compared to untreated controls after 1 hour of co-culture (p<0.05; Fig. 8A) but there was no
statistically significant difference at 3 hours (p>0.05).
We studied the role of direct physical contact between fibroblasts and mast cells in IL-8
release. Mast cells were physically separated from fibroblasts by Cyclopore® membranes during
8 hour co-cultures. IL-8 levels in conditioned media were significantly reduced compared to
conventional mast cell-fibroblast co-cultures (p<0.01; Fig. 8B). Similar results were observed
when fibroblasts were incubated in the presence of sonicated mast cells (p<0.01). Pre-treatment
of mast cell-fibroblast co-cultures with the gap junction inhibitor, BGA, also blocked IL-8
release (p<0.05).
Since cold temperature inhibits gap junction formation [270], IL-8 was quantified in co-
cultures conducted at 4ºC. There was a very large reduction of IL-8 release when co-cultures
were conducted at cold temperature (p<0.001; Fig. 8C).
IL-8 secretion
When fibroblasts and mast cells were pre-treated with brefeldin A to block protein secretion, IL-
8 levels were reduced by >50-fold in both fibroblast monolayer controls and in media derived
from co-cultures (p<0.01; Fig. 9A).
Our data above indicated that there may be an intercellular signal that drives fibroblast
secretion of IL-8. Further, as gap junctions are known to provide a conduit for intercellular
calcium signalling [276], and as previous reports have indicated that IL-8 release from mast cells
can be mediated by perturbation of calcium signalling [277], we considered that IL-8 secretion
may be mediated by calcium signals. Accordingly, we treated cells with thapsigargin to acutely
release Ca2+
from intracellular calcium stores. Treatment of fibroblasts or mast cells for 30
minutes with thapsigargin prior to initiating co-cultures, markedly increased IL-8 levels in the
42
co-culture media compared to untreated groups (p<0.001; Fig. 9B). A similar increase was seen
(p<0.001) when cells were co-cultured and treated with ionomycin, a calcium ionophore. The
effect of thapsigargin was significantly reduced when mast cells were separated from
thapsigargin-treated fibroblasts by Cyclopore® membranes (p<0.01) and also when fibroblasts
were treated with brefeldin A (p<0.01; Fig. 9C), which blocks the protein release pathway in
cells.
Effect of co-culture medium on neutrophil chemotaxis
The data described above showing enhanced IL-8 release into the medium in mast cell-fibroblast
co-cultures, suggested that interactions between these cell types may affect neutrophil
chemotaxis. Accordingly, we determined whether media derived from co-cultures would affect
neutrophil chemotaxis. Assays were conducted using mouse neutrophils that were exposed to 24-
hour conditioned media from either single fibroblast populations or from mast cell-fibroblast co-
cultures. Neutrophil chemotaxis was significantly enhanced in response to co-culture media
compared to media derived from single fibroblast population controls (p<0.01; Fig. 10A).
Notably, the enhanced chemotaxis was significantly reduced when fibroblasts and mast cells
were pre-treated with the gap junction inhibitor, BGA (p<0.001).
43
Discussion
Release of chemoattractants such as IL-8 can exacerbate inflammation by enhancing neutrophil
migration into the lesion [43]. Our principal finding is that direct interactions between human
mast cells and gingival fibroblasts mediate rapid release of IL-8, which promotes neutrophil
chemotaxis [21]. These findings suggest a mechanism by which mast cells and fibroblasts
cooperatively modulate the inflammatory response (Fig. 10B). Their interactions may generate
episodic cycles of remission and acute exacerbation that characterize many types of
inflammatory diseases such as chronic obstructive pulmonary disease [278], inflammatory bowel
diseases [279], arthritis [280] and periodontitis [42].
Fibroblasts are the most abundant cells of soft periodontal connective tissues[139]. While
their principal roles are the synthesis, degradation and remodelling of extracellular matrix
proteins [141], [142], fibroblasts also participate in the inflammatory response through their
interactions with lymphoid and myeloid cells and their production of inflammation-regulating
cytokines [152], [153], [162], [164], [166]. As periodontitis is a high prevalence inflammatory
disease [3] that is characterized by bursts of active tissue destruction followed by periods of
remission and repair [42], we considered that interactions between human gingival fibroblasts
and other normal residents of connective tissues, namely mast cells, may be informative of how
fibroblasts regulate the inflammatory response. Notably, the relative numbers of mast cells in
gingival connective tissues increase during active episodes of periodontitis [222] suggesting that
mast cells may play a crucial role in regulating tissue homeostasis during acute inflammatory
episodes.
44
Mast cell co-culture with fibroblasts increases IL-8 expression
Our data from cytokine arrays showed that human mast cells in co-culture with fibroblasts
induce increased expression of MCP-1, IL-6, GRO and IL-8. MCP-1 is a strong chemoattractant
for monocytes and T-lymphocytes [83] while IL-6 is a pleiotropic inflammatory mediator that
can induce the synthesis of acute phase proteins and enhance B-lymphocyte differentiation and
maturation [281] [282]. Our finding of increased IL-6 levels is consistent with earlier data from
human lung fibroblast-mast cell co-cultures [166]. Two other cytokines were detectably
increased in the antibody arrays, IL-8 and GRO, a member of the IL-8 family. Because
neutrophil chemotaxis is a key feature in acute inflammation, and as IL-8 and GRO are both
potent neutrophil chemoattractants [43], [125], we focused further experiments on how
fibroblasts and mast cells may cooperate to induce IL-8 expression.
We found that IL-8 levels in co-culture-conditioned media were positively associated with
both the duration of co-incubation and the proportion of mast cells that were incubated on the
fibroblasts. Incubation of co-cultures in serum-containing media increased IL-8 levels up to 50-
fold compared to serum-free co-cultures, which may be explained by the presence of vitronectin
(serum spreading factor) an abundant serum protein [283] that facilitates mast cell adhesion and
spreading over fibroblasts [284].
While low baseline levels of IL-8 were detected in HGF cultures, mast cells alone expressed
virtually no IL-8 as measured by ELISA and qRT-PCR (data not shown). Therefore, we consider
that HGFs are the most likely source of the observed, co-culture-induced elevation of IL-8.
Although determining the actual source of IL-8 may be helpful, it should be taken into
consideration that the significance of our findings is in the combined pro-inflammatory effect of
mast cells and fibroblasts in co-culture. Analysis of mRNA by qRT-PCR on flow cytometry-
45
sorted cells following co-culture or immunostaining for IL-8 could be used to identify the cell
population that is the source for the IL-8 released into the medium.
Role of adhesion molecules in co-culture-induced IL-8 expression
Physical separation of mast cells from fibroblasts using Cyclopore® membranes blocked the
release of IL-8 into the medium. These membranes allow free passage of molecules between
cells but prevent direct intercellular contact. In parallel experiments, incubation of fibroblasts
with mast cell sonicates did not mediate increased IL-8 levels. Collectively, these data suggested
that the enhanced IL-8 release that we observed was dependent on intercellular adhesion and
possibly intercellular communication between mast cells and fibroblasts. Previous reports
showed that intercellular contact is essential for co-culture-associated IL-6 expression by HMC-1
mast cells and human lung fibroblasts [166] and that direct interactions between human gingival
fibroblasts and T-lymphocytes induce the expression of IL-1β, IL-1α and IL-6 mRNA [164].
We determined whether IL-8 release involves ligation of fibroblast adhesion receptors.
Fibroblasts were incubated with collagen or N-cadherin-coated polystyrene beads or BSA-coated
beads as controls. Previous analyses of human gingival fibroblasts have established that
receptors for fibrillar collagen [267] and N-cadherin [274] are abundantly expressed by these
cells. None of these molecules enhanced IL-8 release by fibroblasts, suggesting that mechanisms
other than ligation of adhesion receptors may mediate this process. Further, the failure of
homotypic fibroblast co-cultures to increase IL-8 levels supported the specificity of the mast
cell-dependent effect and motivated us to examine in more detail the spatial relationships
between fibroblasts and mast cells in co-cultures.
We studied the strength of intercellular adhesions between fibroblasts and mast cells with
a fluid shear flow assay in later stage cultures [273]. After 24 hours of co-culture phase contrast
46
microscopy showed that mast cells localize and spread over fibroblasts. These cells remained
attached to mast cells following jet washing with buffer at estimated maximum shear stress of
3.5 pascals [273], suggesting that mast cells in co-culture form robust adhesions with gingival
fibroblasts. Notably, histological studies on fibrosis and asthma have demonstrated that mast
cells are located in close proximity to fibroblasts [165], [166], [167] and intimate contacts
between gingival fibroblasts and lymphocytes have been observed in vivo by electron
microscopy [154].
Integrins are heterodimeric glycoproteins that mediate cell attachment to the extracellular
matrix and to other cells [285]. We found that a blocking antibody against β1 integrins
significantly reduced the number of mast cells that attached to fibroblasts at all time points.
Taken together with the collagen bead binding data described above, β1 integrins evidently play
an essential role in intercellular adhesion but that β1 integrin ligation alone is not sufficient for
IL-8 release. β1 integrins are involved in intercellular attachment between T-lymphocytes and
human gingival fibroblasts [162] and in particular, the ICAM-1/LFA-1 pathway is required for
T-cell attachment to fibroblasts [160]. As human gingival fibroblasts express ICAM-1 [162] and
HMC-1 cells express LFA-1[286], our findings are consistent with the possibility that integrins
may mediate fibroblast-mast cell attachments.
Role of gap junctions
Gap junctions are gated membrane channels that allow intercellular passage of small molecules
between attached cells [287]. Several cell types, including gingival and dermal fibroblasts,
establish direct communication and coordinate cellular functions through gap junctions [274],
[288], [289]. Passage of molecules through gap junctions is determined in part by the size of the
molecules [287]. Gap junctions typically permit passage of small molecules such as Ca2+
, IP3,
47
cAMP, and, in our experiments, calcein (molecular mass of <1000 Da), but block passage of
proteins or nucleic acids [275], [287]. The gap junction channel is made of two connexon
structures, for which each cell contributes one connexon. The connexon is composed up of six
connexin proteins embedded within the plasma membrane [290]. Fibroblasts mainly express
connexin 43 (Cx43) [274] while mast cells express Cx43 and Cx32 [291].
Since the elevated co-culture-induced IL-8 was observed within 2 hours of co-culture and
as phase contrast microscopy showed mast cell attachment to fibroblasts, we examined
intercellular communication between these cells by confocal microscopy immediately after
mixing the cells. Fibroblasts were incubated with mast cells that had been labelled previously
with calcein. Live imaging showed gradual dye transfer from mast cells to fibroblasts, which was
detected within 60 minutes after initiation of co-cultures. Analysis of live images in different “z”
sections did not show internalization of mast cells by fibroblasts. Further, to ensure that no free
calcein was present in the mast cell culture media that could have been taken up by the
fibroblasts, as a negative control, we removed mast cells from the medium by filtration and the
filtered medium was then added to fibroblasts. These control cells showed no evidence of dye
uptake after 6 hours of incubation, confirming that there was insufficient free calcein/AM
remaining in the mast cell media (prior to adding them to the fibroblasts) to cause artefactual
staining of the fibroblasts. Therefore, the observed dye in fibroblasts after co-culture indeed
originated from mast cells and not from the medium. As calcein is a small molecule (MW=995
Da) that readily traverses gap junctions [274] [275], we conclude that gap junctions were
involved in intercellular signalling between mast cells and fibroblasts.
We investigated the function of gap junctions between mast cells and fibroblasts using
the gap junction inhibitor BGA. Calcein dye transfer from mast cells into fibroblasts was studied
48
by flow cytometry, which showed that BGA significantly reduced the total number of calcein-
positive cells compared to controls after 1 hour of co-culture but not significantly after 3 hours.
This latter result may have been due to the limitation of flow cytometry in differentiating
between fibroblasts and mast cells based on their sizes. While separation of these cell types
according to forward and side scatter gating was possible at early time periods, by 3 hours it was
difficult to separate the cells with trypsin and to measure their fluorescence separately. Because
of this same challenge in sorting, we were not able to sort and analyze individual cell populations
after the co-culture for qRT-PCR to study IL-8 expression (data not shown).
When we pre-treated mast cells and fibroblasts with BGA, IL-8 levels were significantly
reduced compared to vehicle treated co-cultures. We also found that when cells were co-
incubated at 4ºC, a method that inhibits gap junction formation in vitro [270], IL-8 levels were
virtually undetectable. Although the results from experiments at 4ºC per se do not conclusively
indicate the presence of gap junctions, these findings were in agreement with the notion that gap
junctions play a central role in fibroblast-mast cell interactions that lead to IL-8 release. The
presence of gap junctions between mast cells and fibroblasts was first demonstrated in the
developing avian eye [292] and in vitro studies have shown that rat mast cells can establish gap
junctions with human dermal fibroblasts [244]. Heterotypic gap junctions between mast cells and
dermal fibroblasts can form in collagen lattices but not in monolayer cultures [245]. Our results
in co-cultures indicate that intercellular attachment between fibroblasts and mast cells, and the
subsequent establishment of gap junctions, is required for increased IL-8 release in co-culture.
Previous reports have described a significant increase in IL-6 production 12 to 72 hours
following co-culture of mast cells and fibroblasts [166]. Our data showed a much more rapid
response in which a significant rise of IL-8 levels was detected as early as 2 hours after initiation
49
of co-culture. Further, pre-incubation of cells with brefeldin A, which inhibits protein secretion,
significantly reduced IL-8 levels both in control fibroblasts and in mast cell-fibroblast co-
cultures. Collectively, these data indicate that it is protein secretion and not synthesis that likely
plays a role in the co-culture-induced IL-8 release.
Role of calcium
Gap junctions provide a conduit for intercellular Ca2+
signalling [276] and for transfer of IP3
between cells [293]. IP3 binding to intracellular stores causes Ca2+
release. Since Ca2+
is an
important second messenger that may be involved in intercellular signalling events between
fibroblasts and mast cells, we treated cells with either thapsigargin or ionomycin. Thapsigargin is
a sesquiterpene lactone that inhibits Ca2+
uptake by the endoplasmic reticulum via blocking Ca2+
-
ATPase, which will then lead to increased intracellular Ca2+
[Ca2+
]i [294]. Ionomycin is a
calcium ionophore which directly enhances calcium entry through the plasma membrane, thereby
increasing [Ca2+
]i [295]. A previous report showed that intercellular adhesion between pairs of
homotypic fibroblasts causes increased calcium concentration at contact sites [296]. Our findings
showed that in fibroblast-mast cell co-cultures, both thapsigargin and ionomycin strongly
increased IL-8 release (up to 15-fold of untreated co-cultures). Therefore, we speculate that
intercellular adhesion and increased communication between mast cells and fibroblasts may
enhance IL-8 release by stimulating increased [Ca2+
]i , which then leads to IL-8 release.
Mast cell-fibroblast co-cultures produce soluble factors that enhance neutrophil chemotaxis
IL-8 is a pro-inflammatory cytokine that contributes to acute inflammatory responses by
selectively enhancing neutrophil chemotaxis [21]. We examined the biological implications of
our findings by measuring neutrophil chemotaxis of mouse neutrophils in Zigmond chambers
[272]. We found that neutrophil chemotaxis was significantly increased in response to mast cell-
50
fibroblast co-culture media compared to controls. This effect was significantly inhibited when
the co-cultures were pre-treated with BGA. These data suggest that mast cells, possibly through
the formation of gap junctions with fibroblasts, increase the expression of molecules like IL-8,
which can enhance neutrophil chemotaxis.
Future directions
Studies of lung fibroblasts have shown that CD40, a membrane glycoprotein, is a crucial factor
in fibroblast activation [259]. Ligation of CD40 receptors promotes synthesis of inflammatory
cytokines such as IL-1, IL-6, IL-8, PGs and hyaluronate (an ECM protein) [260], [261], [262].
Expression of CD40 expression has been reported in human gingival fibroblasts [260] and
several cell types including mast cells express CD40 ligand (CD40L) [259]. Conceivably during
co-culture, mast cells may activate gingival fibroblasts through CD40-CD40 ligand interactions,
thereby enhancing IL-8 expression. Further experiments may be appropriate to examine the
possible involvement of CD40 in fibroblast-mast cell-associated IL-8 release. Improved
understanding of how a major mast cell mediator such as histamine may interact with fibroblasts
could be helpful in understanding HMC/HGF pro-inflammatory interactions. Ultimately, after
the actual mechanism for this phenomenon is identified, a clinical study on targeting pro-
inflammatory interactions between mast cells and fibroblasts in patients with chronic
inflammatory diseases such as refractory periodontitis would be important.
Figure 5
0
10
20
30
40
50
60
70
0 hr 1 hr 2 hr 4 hr 6 hr 8 hr
HGF Control
HGF/HMC Co-culture
Hours of incubation
IL-8
pg
/ml
**
*
*
0
500
1000
1500
2000
2500
3000
0 hr 1 hr 2 hr 4 hr 6 hr 8 hr
HGF in (αMEM+FBS)
HGF & HMC in (αMEM+FBS)
IL-8
pg
/ml
Hours of incubation
**
*
*
0
2
4
6
8
10
12
14
16
HGF Control HMC Control HGF/HMC Co-culture
IL-8
pg
/ml
*
0
100
200
300
400
500
600
HGF + HMC
RATIO = 2:1
HGF + HMC
RATIO = 1:1
HGF + HMC
RATIO = 1:2
HGF + HMC
RATIO = 1:4
200,000 HMC
400,000 HMC
IL-8
pg
/ml
**
**
***
A
B C
D E
52
Fig. 5. (A) Human antibody cytokine array to assess inflammatory cytokines in HGF/HMC co-
culture. After 8 hours of co-culture there were increased levels of several inflammatory cytokines
including IL-8, GRO (IL-8-related chemokine), IL-6 and MCP-1 (CCL2) compared to control
fibroblasts, which were cultured in the absence of mast cells. (B) IL-8 quantification of
HGF/HMC co-culture in serum-free media for 8 hours. IL-8 was quantified by ELISA. *
indicates p<0.001 different than fibroblasts and mast cells control groups. (C) Dose-response
effect between relative numbers of mast cells to fibroblasts and levels of IL-8 in HGF/HMC co-
culture. * indicates p<0.001, ** indicates p<0.05 and *** indicates p<0.01when comparing co-
cultures with different ratios of mast cells to fibroblasts. (D,E) The effect of co-incubation time
on IL-8 levels in serum-free (D) and serum-containing (E) media. * in (D) indicates p<0.01 and
* in (E) indicates p<0.001 different than IL-8 concentration in HGF control at same time point.
0
200
400
600
800
1000
1200
1400
1600
1800
0 hr 1 hr 2 hr 4 hr
HGF in (αMEM + FBS)
HGF/HMC in (αMEM + FBS)
HGF/BSA beads in (αMEM + FBS)
IL-8
pg
/ml
Hours of incubation
0
200
400
600
800
1000
1200
1400
1600
1800
2000
HGF HGF+ BSA BEADS
HGF+ N CAD BEADS
HGF+ Collagen BEADS
HGF+ HGF HGF+ HMC
IL-8
pg
/ml
IL-8 levels after 4 hours of co-incubation
*
*
*
Figure 6
A
B
54
Fig. 6. Role of adhesion molecules in co-culture-induced IL-8 release. (A) IL-8 concentration in
HGF/HMC co-culture was compared to HGF control and HGF co-incubated with BSA-coated
beads at 0, 1, 2 and 4 hours. * indicates p<0.001different than HGF control and HGF + BSA
coated beads. (B) IL-8 concentration in HGF/HMC co-culture was compared to those in HGF
control, HGF co-incubated with BSA, N-cadherin or collagen coated beads and homotypic
HGF/HGF co-culture at 4 hours. * indicates p<0.001different than all other groups.
Figure 7
CA B
0.0
0.5
1.0
1.5
2.0
2.5
1 hr 3 hr 6 hr
Control
+4B4 Antibody
HM
C/H
GF
Rati
o
Role of Integrins in HMC/HGF attachment
Hours of co-culture
*
*
**
D
HMC
HGF
0 Min
30 Min 60 Min 90 Min 120 Min
150 Min 180 Min 210 Min 240 Min
270 Min 300 Min 330 Min 360 Min
56
Fig. 7. (A,B) Phase contrast microscopy: HGF (A) and HGF/HMC co-culture (B) after
incubation for 24 hours, followed by jet wash with PBS. (C) Role of integrins in HGF/HMC
attachment examined with 4B4 antibody to block β1 integrins. Cells were labelled with
fluorescein dextran. Fluorescence microscopy was used to estimate the ratio of attached HMCs
to HGF after rinse with PBS at 1, 3 and 6 hours of co-culture. * indicates p<0.05 and **
indicates p<0.01 different than the 4B4 untreated co-culture control. (D) Live imaging with
laser-scanning confocal microscopy: HMC-1 (donor) were loaded with calcein/AM (green) and
were plated on to established HGF monolayer (acceptor). Over 6 hours, there was gradual dye
transfer from HMCs into HGFs.
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
HGF/HMC Co-culture HMC on membrane HMC Sonicate + HGF HGF/HMC + BGA
IL-8
pg
/ m
l
**
**
0.00
0.50
1.00
1.50
2.00
2.50
3.00
1 3
Time of HMC Co-Incubation with HGF (Hours)
Without BGA Total FL
With BGA Total FL
Effect of BGA on dye transfer
To
tal P
op
ula
tio
n
Calc
ein
Flu
ore
scen
ce
(Ch
an
nn
elN
um
ber)
*
0
2
4
6
8
10
12
HGF at 37⁰C HGF + HMC at 37⁰C
HGF at 4°C HGF+HMC at 4°C
IL-8
pg
/ml
*
Figure 8
A
C
B
58
Fig. 8. (A) Flow cytometry for analyzing effect of gap junction inhibitor (BGA) on dye transfer
between HMCs and HGFs after 1 or 3 hours of co-incubation. * indicates p<0.05 different than
untreated co-cultures at same time point. (B) Role of direct cell-cell contact and gap junctions
between HMC-1 and HGF on IL-8 expression. For the first group, HGF/HMC co-culture was
used as control. In the second group, HMCs were physically separated from HGFs by
Cyclopore® membranes. For the third group, HGFs were incubated with HMC-1 sonicates. For
the fourth group, co-cultures were established in the presence of gap junction inhibitor (BGA). *
indicates p<0.01 and ** indicates p<0.05 different than HGF/HMC control group with regards to
IL-8 concentration in conditioned media. (C) Effect of cold as an inhibitor of gap junction
formation. IL-8 concentrations measured in regular cultures at 37ºC compared to cultures at 4ºC.
* indicates p<0.001different than all other groups.
0
500
1000
1500
2000
2500
3000
HGF/HMC Co-culture HGF/TSGN + HMC HMC/TSGN + HGF HGF/HMC + Ionomycin
IL-8
pg
/ml
*
**
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
HGF + aMEM/DMSO HGF + aMEM/BFA HGF + HMC/DMSO HGF + HMC/BFA
IL-8
pg
/ml
*
0
500
1000
1500
2000
2500
3000
HGF/TSGN + HMC (HGF+TSGN) + HMC on membrane
[(HGF+TSGN) + HMC] + Brefeldin-A
IL-8
pg
/ m
l
**
*
Figure 9
A
B
C
60
Fig. 9. (A) Effect of protein secretion block on IL-8 levels. Cells were treated with brefeldin A
(BFA). IL-8 levels were measured after 8 hours of co-culture. * indicates p<0.01 different than
BFA untreated cells. (B) Role of calcium in co-culture-induced IL-8 expression. Cells were
treated with thapsigargin (TSGN) to release calcium from intracellular stores or with ionomycin
to allow calcium entry from the extracellular space. * indicates p<0.001 different than untreated
HGF/HMC co-cultures. (C) Role of direct HGF-HMC contact and protein secretion in calcium-
mediated IL-8 expression in co-culture. In the first group (control) HGFs were treated with
TSGN followed by co-incubation with HMC-1. In the second group, mast cells were separated
from HGFs by Cyclopore® membranes. For the third group, HGFs and HMCs were treated with
BFA. * indicates p<0.01different than control group.
0
1
2
3
4
5
6
7
HGF HMC HMC+HGF fMLP
Ave
rag
e S
pee
d
µm
/min
Neutrophil Chemotaxis Assay
Untreated
BGA treated
*
**
Mast cells
NeutrophilChemotaxis
↑ IL-8
AcuteInflammation
Tissue destruction
RepairRegeneration
Fibroblasts
Proposed model for mast cell-fibroblast interactions that regulate
the acute inflammatory response
Figure 10
B
A
62
Fig. 10. (A) Effect of HGF/HMC co-culture medium on neutrophil chemotaxis. Migratory speed
of neutrophils was significantly enhanced in response to HGF/HMC co-culture media compared
to media derived from homotypic cell population controls. This effect was inhibited when co-
cultures were incubated with BGA. * indicates p<0.01different than HGF and HMC controls. **
indicates p<0.001 different than BGA untreated HGF/HMC co-culture group. (B) Proposed
model for mast cell-fibroblast interactions in regulation of inflammation.
63
References
[1] AAP, Glossary of Periodontal Terms The American Academy of Periodontology 4th
Edition (2001).
[2] J.M. Albandar, J.A. Brunelle, A. Kingman, Destructive periodontal disease in adults 30
years of age and older in the United States, 1988-1994, J Periodontol 70 (1999) 13-29.
[3] R.C. Oliver, L.J. Brown, H. Loe, Periodontal diseases in the United States population, J
Periodontol 69 (1998) 269-278.
[4] P.N. Papapanou, Periodontal diseases: epidemiology, Annals of periodontology / the
American Academy of Periodontology 1 (1996) 1-36.
[5] D. Kinane, P. Bouchard, Periodontal diseases and health: Consensus Report of the Sixth
European Workshop on Periodontology, J Clin Periodontol 35 (2008) 333-337.
[6] F.A. Scannapieco, R.B. Bush, S. Paju, Associations between periodontal disease and risk
for atherosclerosis, cardiovascular disease, and stroke. A systematic review, Annals of
periodontology / the American Academy of Periodontology 8 (2003) 38-53.
[7] W.J. Teeuw, V.E. Gerdes, B.G. Loos, Effect of periodontal treatment on glycemic control
of diabetic patients: a systematic review and meta-analysis, Diabetes care 33 (2010) 421-
427.
[8] F.A. Scannapieco, R.B. Bush, S. Paju, Periodontal disease as a risk factor for adverse
pregnancy outcomes. A systematic review, Annals of periodontology / the American
Academy of Periodontology 8 (2003) 70-78.
[9] R.I. Garcia, M.E. Nunn, P.S. Vokonas, Epidemiologic associations between periodontal
disease and chronic obstructive pulmonary disease, Annals of periodontology / the
American Academy of Periodontology 6 (2001) 71-77.
[10] F.A. Scannapieco, M.P. Rethman, The relationship between periodontal diseases and
respiratory diseases, Dentistry today 22 (2003) 79-83.
[11] D.S. Michaud, Y. Liu, M. Meyer, E. Giovannucci, K. Joshipura, Periodontal disease,
tooth loss, and cancer risk in male health professionals: a prospective cohort study, The
lancet oncology 9 (2008) 550-558.
[12] K.S. Kornman, A. Crane, H.Y. Wang, F.S. di Giovine, M.G. Newman, F.W. Pirk, T.G.
Wilson, Jr., F.L. Higginbottom, G.W. Duff, The interleukin-1 genotype as a severity
factor in adult periodontal disease, J Clin Periodontol 24 (1997) 72-77.
[13] B.S. Michalowicz, S.R. Diehl, J.C. Gunsolley, B.S. Sparks, C.N. Brooks, T.E. Koertge,
J.V. Califano, J.A. Burmeister, H.A. Schenkein, Evidence of a substantial genetic basis
for risk of adult periodontitis, J Periodontol 71 (2000) 1699-1707.
[14] C.L. Lavelle, The immune response to oral infections, Dental update 19 (1992) 14-20.
[15] R.P. Darveau, A. Tanner, R.C. Page, The microbial challenge in periodontitis,
Periodontology 2000 14 (1997) 12-32.
[16] A.D. Haffajee, S.S. Socransky, Introduction to microbial aspects of periodontal biofilm
communities, development and treatment, Periodontology 2000 42 (2006) 7-12.
[17] D.J. Bradshaw, P.D. Marsh, G.K. Watson, C. Allison, Role of Fusobacterium nucleatum
and coaggregation in anaerobe survival in planktonic and biofilm oral microbial
communities during aeration, Infection and immunity 66 (1998) 4729-4732.
[18] S.S. Socransky, A.D. Haffajee, M.A. Cugini, C. Smith, R.L. Kent, Jr., Microbial
complexes in subgingival plaque, J Clin Periodontol 25 (1998) 134-144.
64
[19] A. Kantarci, T.E. Van Dyke, Neutrophil-mediated host response to Porphyromonas
gingivalis, Journal of the International Academy of Periodontology 4 (2002) 119-125.
[20] D. Matthews, Conclusive support for mechanical nonsurgical pocket therapy in the
treatment of periodontal disease. How effective is mechanical nonsurgical pocket
therapy?, Evidence-based dentistry 6 (2005) 68-69.
[21] M. Baggiolini, A. Walz, S.L. Kunkel, Neutrophil-activating peptide-1/interleukin 8, a
novel cytokine that activates neutrophils, The Journal of clinical investigation 84 (1989)
1045-1049.
[22] M. Bickel, The role of interleukin-8 in inflammation and mechanisms of regulation, J
Periodontol 64 (1993) 456-460.
[23] L.J. Jin, W.K. Leung, E.F. Corbet, B. Soder, Relationship of changes in interleukin-8
levels and granulocyte elastase activity in gingival crevicular fluid to subgingival
periodontopathogens following non-surgical periodontal therapy in subjects with chronic
periodontitis, J Clin Periodontol 29 (2002) 604-614.
[24] R.C. Page, H.E. Schroeder, Pathogenesis of inflammatory periodontal disease. A
summary of current work, Laboratory investigation; a journal of technical methods and
pathology 34 (1976) 235-249.
[25] G.C. Armitage, Clinical evaluation of periodontal diseases, Periodontology 2000 7 (1995)
39-53.
[26] H. Birkedal-Hansen, Role of cytokines and inflammatory mediators in tissue destruction,
J Periodontal Res 28 (1993) 500-510.
[27] R.J. Genco, J. Slots, Host responses in periodontal diseases, Journal of dental research 63
(1984) 441-451.
[28] S. Offenbacher, P.A. Heasman, J.G. Collins, Modulation of host PGE2 secretion as a
determinant of periodontal disease expression, J Periodontol 64 (1993) 432-444.
[29] J.J. Reynolds, M.C. Meikle, Mechanisms of connective tissue matrix destruction in
periodontitis, Periodontology 2000 14 (1997) 144-157.
[30] F.A. Roberts, L.S. Houston, S.A. Lukehart, L.A. Mancl, G.R. Persson, R.C. Page,
Periodontitis vaccine decreases local prostaglandin E2 levels in a primate model,
Infection and immunity 72 (2004) 1166-1168.
[31] T. Takata, K. Donath, The mechanism of pocket formation. A light microscopic study on
undecalcified human material, J Periodontol 59 (1988) 215-221.
[32] J. Waerhaug, Subgingival plaque and loss of attachment in periodontosis as observed in
autopsy material, J Periodontol 47 (1976) 636-642.
[33] J.K. Heath, S.J. Atkinson, R.M. Hembry, J.J. Reynolds, M.C. Meikle, Bacterial antigens
induce collagenase and prostaglandin E2 synthesis in human gingival fibroblasts through
a primary effect on circulating mononuclear cells, Infection and immunity 55 (1987)
2148-2154.
[34] M.C. Meikle, J.K. Heath, J.J. Reynolds, Advances in understanding cell interactions in
tissue resorption. Relevance to the pathogenesis of periodontal diseases and a new
hypothesis, Journal of oral pathology 15 (1986) 239-250.
[35] M.C. Meikle, S.J. Atkinson, R.V. Ward, G. Murphy, J.J. Reynolds, Gingival fibroblasts
degrade type I collagen films when stimulated with tumor necrosis factor and interleukin
1: evidence that breakdown is mediated by metalloproteinases, J Periodontal Res 24
(1989) 207-213.
65
[36] M. Oido-Mori, R. Rezzonico, P.L. Wang, Y. Kowashi, J.M. Dayer, P.C. Baehni, C.
Chizzolini, Porphyromonas gingivalis gingipain-R enhances interleukin-8 but decreases
gamma interferon-inducible protein 10 production by human gingival fibroblasts in
response to T-cell contact, Infection and immunity 69 (2001) 4493-4501.
[37] N. Tomi, Y. Fukuyo, S. Arakawa, T. Nakajima, Pro-inflammatory cytokine production
from normal human fibroblasts is induced by Tannerella forsythia detaching factor, J
Periodontal Res 43 (2008) 136-142.
[38] J. Gamonal, A. Acevedo, A. Bascones, O. Jorge, A. Silva, Levels of interleukin-1 beta, -
8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult
periodontitis patients and the effect of periodontal treatment, J Periodontol 71 (2000)
1535-1545.
[39] D.H. Thunell, K.D. Tymkiw, G.K. Johnson, S. Joly, K.K. Burnell, J.E. Cavanaugh, K.A.
Brogden, J.M. Guthmiller, A multiplex immunoassay demonstrates reductions in gingival
crevicular fluid cytokines following initial periodontal therapy, J Periodontal Res (2009).
[40] C.C. Tsai, Y.P. Ho, C.C. Chen, Levels of interleukin-1 beta and interleukin-8 in gingival
crevicular fluids in adult periodontitis, J Periodontol 66 (1995) 852-859.
[41] H. Loe, A. Anerud, H. Boysen, M. Smith, The natural history of periodontal disease in
man. The rate of periodontal destruction before 40 years of age, J Periodontol 49 (1978)
607-620.
[42] S.S. Socransky, A.D. Haffajee, J.M. Goodson, J. Lindhe, New concepts of destructive
periodontal disease, J Clin Periodontol 11 (1984) 21-32.
[43] C. Nathan, Neutrophils and immunity: challenges and opportunities, Nature reviews 6
(2006) 173-182.
[44] D.R. Miller, I.B. Lamster, A.I. Chasens, Role of the polymorphonuclear leukocyte in
periodontal health and disease, J Clin Periodontol 11 (1984) 1-15.
[45] S.J. Klebanoff, R.A. Clark, The Neutrophil: Function and Clinical Disorders,
Elsevier/North Holland, Amsterdam, 1978.
[46] M. Anastassova-Kristeva, The origin and development of the immune system with a view
to stem cell therapy, Journal of hematotherapy & stem cell research 12 (2003) 137-154.
[47] I.R. Williams, C.A. Parkos, Colonic neutrophils in inflammatory bowel disease: double-
edged swords of the innate immune system with protective and destructive capacity,
Gastroenterology 133 (2007) 2049-2052.
[48] S.W. Edwards, M.B. Hallett, Seeing the wood for the trees: the forgotten role of
neutrophils in rheumatoid arthritis, Immunology today 18 (1997) 320-324.
[49] A. Kantarci, K. Oyaizu, T.E. Van Dyke, Neutrophil-mediated tissue injury in periodontal
disease pathogenesis: findings from localized aggressive periodontitis, J Periodontol 74
(2003) 66-75.
[50] W. Lee, S. Aitken, J. Sodek, C.A. McCulloch, Evidence of a direct relationship between
neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active
enzyme in human periodontitis, J Periodontal Res 30 (1995) 23-33.
[51] D.H. Adams, S. Shaw, Leucocyte-endothelial interactions and regulation of leucocyte
migration, Lancet 343 (1994) 831-836.
[52] K.S. Kornman, R.C. Page, M.S. Tonetti, The host response to the microbial challenge in
periodontitis: assembling the players, Periodontology 2000 14 (1997) 33-53.
66
[53] R.P. McEver, Leukocyte-endothelial cell interactions, Current opinion in cell biology 4
(1992) 840-849.
[54] M.A. Arnaout, Structure and function of the leukocyte adhesion molecules CD11/CD18,
Blood 75 (1990) 1037-1050.
[55] M.S. Kluger, Vascular endothelial cell adhesion and signaling during leukocyte
recruitment, Advances in dermatology 20 (2004) 163-201.
[56] J.S. Pober, Effects of tumour necrosis factor and related cytokines on vascular endothelial
cells, Ciba Foundation symposium 131 (1987) 170-184.
[57] N.T. Luu, G.E. Rainger, G.B. Nash, Kinetics of the different steps during neutrophil
migration through cultured endothelial monolayers treated with tumour necrosis factor-
alpha, Journal of vascular research 36 (1999) 477-485.
[58] C. Johnson-Leger, B.A. Imhof, Forging the endothelium during inflammation: pushing at
a half-open door?, Cell and tissue research 314 (2003) 93-105.
[59] F.W. Luscinskas, S. Ma, A. Nusrat, C.A. Parkos, S.K. Shaw, Leukocyte transendothelial
migration: a junctional affair, Seminars in immunology 14 (2002) 105-113.
[60] D. Feng, J.A. Nagy, K. Pyne, H.F. Dvorak, A.M. Dvorak, Neutrophils emigrate from
venules by a transendothelial cell pathway in response to FMLP, The Journal of
experimental medicine 187 (1998) 903-915.
[61] L. Stephens, L. Milne, P. Hawkins, Moving towards a better understanding of
chemotaxis, Curr Biol 18 (2008) R485-494.
[62] D.K. Dennison, T.E. Van Dyke, The acute inflammatory response and the role of
phagocytic cells in periodontal health and disease, Periodontology 2000 14 (1997) 54-78.
[63] M.B. Hallett, Controlling the molecular motor of neutrophil chemotaxis, Bioessays 19
(1997) 615-621.
[64] M. Baggiolini, B. Dewald, B. Moser, Human chemokines: an update, Annual review of
immunology 15 (1997) 675-705.
[65] M.B. Hallett, A.K. Campbell, Measurement of changes in cytoplasmic free CA2+ in
fused cell hybrids, Nature 295 (1982) 155-158.
[66] A.S. Kraft, R.L. Berkow, Tyrosine kinase and phosphotyrosine phosphatase activity in
human promyelocytic leukemia cells and human polymorphonuclear leukocytes, Blood
70 (1987) 356-362.
[67] J. Gomez-Cambronero, C.K. Huang, V.A. Bonak, E. Wang, J.E. Casnellie, T. Shiraishi,
R.I. Sha'afi, Tyrosine phosphorylation in human neutrophil, Biochemical and biophysical
research communications 162 (1989) 1478-1485.
[68] J. Gomez-Cambronero, E. Wang, G. Johnson, C.K. Huang, R.I. Sha'afi, Platelet-
activating factor induces tyrosine phosphorylation in human neutrophils, The Journal of
biological chemistry 266 (1991) 6240-6245.
[69] J.P. Robinson, G.F. Babcock, Phagocyte Function: A Guide For Research And Clinical
Evaluation, A John Wiley and Sons Inc., USA, 1998.
[70] S.C. Silverstein, R.M. Steinman, Z.A. Cohn, Endocytosis, Annual review of biochemistry
46 (1977) 669-722.
[71] J.A. Badwey, M.L. Karnovsky, Active oxygen species and the functions of phagocytic
leukocytes, Annual review of biochemistry 49 (1980) 695-726.
[72] J.E. Jordan, Z.Q. Zhao, J. Vinten-Johansen, The role of neutrophils in myocardial
ischemia-reperfusion injury, Cardiovascular research 43 (1999) 860-878.
67
[73] T.E. Van Dyke, G.A. Hoop, Neutrophil function and oral disease, Crit Rev Oral Biol
Med 1 (1990) 117-133.
[74] A.D. Haffajee, S.S. Socransky, M.A. Taubman, J. Sioson, D.J. Smith, Patterns of
antibody response in subjects with periodontitis, Oral microbiology and immunology 10
(1995) 129-137.
[75] R. Lakshman, A. Finn, Neutrophil disorders and their management, Journal of clinical
pathology 54 (2001) 7-19.
[76] S. Deguchi, T. Hori, H. Creamer, W. Gabler, Neutrophil-mediated damage to human
periodontal ligament-derived fibroblasts: role of lipopolysaccharide, J Periodontal Res 25
(1990) 293-299.
[77] P.M. Henson, R.B. Johnston, Jr., Tissue injury in inflammation. Oxidants, proteinases,
and cationic proteins, The Journal of clinical investigation 79 (1987) 669-674.
[78] M.I. Fredriksson, A.K. Gustafsson, K.G. Bergstrom, B.E. Asman, Constitutionally
hyperreactive neutrophils in periodontitis, J Periodontol 74 (2003) 219-224.
[79] I.B. Lamster, E. Kaufman, J.T. Grbic, L.J. Winston, R.E. Singer, Beta-glucuronidase
activity in saliva: relationship to clinical periodontal parameters, J Periodontol 74 (2003)
353-359.
[80] K. Shibata, M.L. Warbington, B.J. Gordon, H. Kurihara, T.E. Van Dyke, Nitric oxide
synthase activity in neutrophils from patients with localized aggressive periodontitis, J
Periodontol 72 (2001) 1052-1058.
[81] N. Mukaida, Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases,
Am J Physiol Lung Cell Mol Physiol 284 (2003) L566-577.
[82] L. Stievano, E. Piovan, A. Amadori, C and CX3C chemokines: cell sources and
physiopathological implications, Critical reviews in immunology 24 (2004) 205-228.
[83] T.J. Schall, K.B. Bacon, Chemokines, leukocyte trafficking, and inflammation, Current
opinion in immunology 6 (1994) 865-873.
[84] E.J. Leonard, T. Yoshimura, Human monocyte chemoattractant protein-1 (MCP-1),
Immunology today 11 (1990) 97-101.
[85] R.S. Selvan, J.H. Butterfield, M.S. Krangel, Expression of multiple chemokine genes by
a human mast cell leukemia, The Journal of biological chemistry 269 (1994) 13893-
13898.
[86] S.K. Ahuja, P.M. Murphy, The CXC chemokines growth-regulated oncogene (GRO)
alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived
neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A,
human interleukin-8 receptor, The Journal of biological chemistry 271 (1996) 20545-
20550.
[87] R.M. Strieter, P.J. Polverini, D.A. Arenberg, A. Walz, G. Opdenakker, J. Van Damme,
S.L. Kunkel, Role of C-X-C chemokines as regulators of angiogenesis in lung cancer,
Journal of leukocyte biology 57 (1995) 752-762.
[88] K.E. Cole, C.A. Strick, T.J. Paradis, K.T. Ogborne, M. Loetscher, R.P. Gladue, W. Lin,
J.G. Boyd, B. Moser, D.E. Wood, B.G. Sahagan, K. Neote, Interferon-inducible T cell
alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity
on activated T cells through selective high affinity binding to CXCR3, The Journal of
experimental medicine 187 (1998) 2009-2021.
68
[89] A. Martin-Fontecha, L.L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, F.
Sallusto, Induced recruitment of NK cells to lymph nodes provides IFN-gamma for
T(H)1 priming, Nature immunology 5 (2004) 1260-1265.
[90] H. Soto, W. Wang, R.M. Strieter, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, J. Hedrick,
A. Zlotnik, The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3,
Proceedings of the National Academy of Sciences of the United States of America 95
(1998) 8205-8210.
[91] K. Hattermann, J. Held-Feindt, R. Lucius, S.S. Muerkoster, M.E. Penfold, T.J. Schall, R.
Mentlein, The chemokine receptor CXCR7 is highly expressed in human glioma cells
and mediates antiapoptotic effects, Cancer research 70 3299-3308.
[92] P.M. Murphy, I.F. Charo, R. Hills, R. Horuk, K. Matsushima, J.J. Oppenheim,
Chemokine receptors, IUPHAR database, 2010.
[93] J.F. Bazan, K.B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D.R. Greaves, A.
Zlotnik, T.J. Schall, A new class of membrane-bound chemokine with a CX3C motif,
Nature 385 (1997) 640-644.
[94] A.M. Fong, L.A. Robinson, D.A. Steeber, T.F. Tedder, O. Yoshie, T. Imai, D.D. Patel,
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm
adhesion, and activation under physiologic flow, The Journal of experimental medicine
188 (1998) 1413-1419.
[95] J.G. D'Haese, I.E. Demir, H. Friess, G.O. Ceyhan, Fractalkine/CX3CR1: why a single
chemokine-receptor duo bears a major and unique therapeutic potential, Expert opinion
on therapeutic targets 14 (2010) 207-219.
[96] P.M. Murphy, M. Baggiolini, I.F. Charo, C.A. Hebert, R. Horuk, K. Matsushima, L.H.
Miller, J.J. Oppenheim, C.A. Power, International union of pharmacology. XXII.
Nomenclature for chemokine receptors, Pharmacological reviews 52 (2000) 145-176.
[97] A. Zlotnik, O. Yoshie, Chemokines: a new classification system and their role in
immunity, Immunity 12 (2000) 121-127.
[98] K. Matsushima, K. Morishita, T. Yoshimura, S. Lavu, Y. Kobayashi, W. Lew, E.
Appella, H.F. Kung, E.J. Leonard, J.J. Oppenheim, Molecular cloning of a human
monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF
mRNA by interleukin 1 and tumor necrosis factor, The Journal of experimental medicine
167 (1988) 1883-1893.
[99] C.A. Hebert, F.W. Luscinskas, J.M. Kiely, E.A. Luis, W.C. Darbonne, G.L. Bennett, C.C.
Liu, M.S. Obin, M.A. Gimbrone, Jr., J.B. Baker, Endothelial and leukocyte forms of IL-
8. Conversion by thrombin and interactions with neutrophils, J Immunol 145 (1990)
3033-3040.
[100] H. Nakagawa, S. Hatakeyama, A. Ikesue, H. Miyai, Generation of interleukin-8 by
plasmin from AVLPR-interleukin-8, the human fibroblast-derived neutrophil chemotactic
factor, FEBS letters 282 (1991) 412-414.
[101] M. Padrines, M. Wolf, A. Walz, M. Baggiolini, Interleukin-8 processing by neutrophil
elastase, cathepsin G and proteinase-3, FEBS letters 352 (1994) 231-235.
[102] T. Yoshimura, E.A. Robinson, E. Appella, K. Matsushima, S.D. Showalter, A. Skeel, E.J.
Leonard, Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF)
distinguished by different lengths of the amino-terminal sequence, Molecular
immunology 26 (1989) 87-93.
69
[103] Y.C. Ko, N. Mukaida, S. Ishiyama, A. Tokue, T. Kawai, K. Matsushima, T. Kasahara,
Elevated interleukin-8 levels in the urine of patients with urinary tract infections,
Infection and immunity 61 (1993) 1307-1314.
[104] E.T. Baldwin, I.T. Weber, R. St Charles, J.C. Xuan, E. Appella, M. Yamada, K.
Matsushima, B.F. Edwards, G.M. Clore, A.M. Gronenborn, et al., Crystal structure of
interleukin 8: symbiosis of NMR and crystallography, Proceedings of the National
Academy of Sciences of the United States of America 88 (1991) 502-506.
[105] S.D. Burrows, M.L. Doyle, K.P. Murphy, S.G. Franklin, J.R. White, I. Brooks, D.E.
McNulty, M.O. Scott, J.R. Knutson, D. Porter, et al., Determination of the monomer-
dimer equilibrium of interleukin-8 reveals it is a monomer at physiological
concentrations, Biochemistry 33 (1994) 12741-12745.
[106] J.F. Paolini, D. Willard, T. Consler, M. Luther, M.S. Krangel, The chemokines IL-8,
monocyte chemoattractant protein-1, and I-309 are monomers at physiologically relevant
concentrations, J Immunol 153 (1994) 2704-2717.
[107] N. Mukaida, Interleukin-8: an expanding universe beyond neutrophil chemotaxis and
activation, International journal of hematology 72 (2000) 391-398.
[108] N. Mukaida, A. Harada, K. Yasumoto, K. Matsushima, Properties of pro-inflammatory
cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte
chemotactic and activating factor (MCAF), Microbiology and immunology 36 (1992)
773-789.
[109] J.J. Oppenheim, C.O. Zachariae, N. Mukaida, K. Matsushima, Properties of the novel
proinflammatory supergene "intercrine" cytokine family, Annual review of immunology
9 (1991) 617-648.
[110] M.J. Alcorn, J.L. Booth, K.M. Coggeshall, J.P. Metcalf, Adenovirus type 7 induces
interleukin-8 production via activation of extracellular regulated kinase 1/2, Journal of
virology 75 (2001) 6450-6459.
[111] A. Casola, R.P. Garofalo, M. Jamaluddin, S. Vlahopoulos, A.R. Brasier, Requirement of
a novel upstream response element in respiratory syncytial virus-induced IL-8 gene
expression, J Immunol 164 (2000) 5944-5951.
[112] Y. Mahe, N. Mukaida, K. Kuno, M. Akiyama, N. Ikeda, K. Matsushima, S. Murakami,
Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on
nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements, The Journal
of biological chemistry 266 (1991) 13759-13763.
[113] N. Mori, N. Mukaida, D.W. Ballard, K. Matsushima, N. Yamamoto, Human T-cell
leukemia virus type I Tax transactivates human interleukin 8 gene through acting
concurrently on AP-1 and nuclear factor-kappaB-like sites, Cancer research 58 (1998)
3993-4000.
[114] M. Kunz, A. Hartmann, E. Flory, A. Toksoy, D. Koczan, H.J. Thiesen, N. Mukaida, M.
Neumann, U.R. Rapp, E.B. Brocker, R. Gillitzer, Anoxia-induced up-regulation of
interleukin-8 in human malignant melanoma. A potential mechanism for high tumor
aggressiveness, The American journal of pathology 155 (1999) 753-763.
[115] L. Xu, K. Xie, N. Mukaida, K. Matsushima, I.J. Fidler, Hypoxia-induced elevation in
interleukin-8 expression by human ovarian carcinoma cells, Cancer research 59 (1999)
5822-5829.
70
[116] Y.M. Janssen-Heininger, M.E. Poynter, P.A. Baeuerle, Recent advances towards
understanding redox mechanisms in the activation of nuclear factor kappaB, Free radical
biology & medicine 28 (2000) 1317-1327.
[117] W.E. Holmes, J. Lee, W.J. Kuang, G.C. Rice, W.I. Wood, Structure and functional
expression of a human interleukin-8 receptor, Science (New York, N.Y 253 (1991) 1278-
1280.
[118] P.M. Murphy, H.L. Tiffany, Cloning of complementary DNA encoding a functional
human interleukin-8 receptor, Science (New York, N.Y 253 (1991) 1280-1283.
[119] C. Murdoch, CXCR4: chemokine receptor extraordinaire, Immunological reviews 177
(2000) 175-184.
[120] A.K. Samanta, J.J. Oppenheim, K. Matsushima, Interleukin 8 (monocyte-derived
neutrophil chemotactic factor) dynamically regulates its own receptor expression on
human neutrophils, The Journal of biological chemistry 265 (1990) 183-189.
[121] G. Servant, O.D. Weiner, P. Herzmark, T. Balla, J.W. Sedat, H.R. Bourne, Polarization of
chemoattractant receptor signaling during neutrophil chemotaxis, Science (New York,
N.Y 287 (2000) 1037-1040.
[122] Z. Li, H. Jiang, W. Xie, Z. Zhang, A.V. Smrcka, D. Wu, Roles of PLC-beta2 and -beta3
and PI3Kgamma in chemoattractant-mediated signal transduction, Science (New York,
N.Y 287 (2000) 1046-1049.
[123] E. Hirsch, V.L. Katanaev, C. Garlanda, O. Azzolino, L. Pirola, L. Silengo, S. Sozzani, A.
Mantovani, F. Altruda, M.P. Wymann, Central role for G protein-coupled
phosphoinositide 3-kinase gamma in inflammation, Science (New York, N.Y 287 (2000)
1049-1053.
[124] D.R. Dixon, B.W. Bainbridge, R.P. Darveau, Modulation of the innate immune response
within the periodontium, Periodontology 2000 35 (2004) 53-74.
[125] M. Baggiolini, B. Dewald, B. Moser, Interleukin-8 and related chemotactic cytokines--
CXC and CC chemokines, Advances in immunology 55 (1994) 97-179.
[126] A. Mathur, B. Michalowicz, M. Castillo, D. Aeppli, Interleukin-1 alpha, interleukin-8 and
interferon-alpha levels in gingival crevicular fluid, J Periodontal Res 31 (1996) 489-495.
[127] A. Sakai, M. Ohshima, N. Sugano, K. Otsuka, K. Ito, Profiling the cytokines in gingival
crevicular fluid using a cytokine antibody array, J Periodontol 77 (2006) 856-864.
[128] J.E. Fitzgerald, D.L. Kreutzer, Localization of interleukin-8 in human gingival tissues,
Oral microbiology and immunology 10 (1995) 297-303.
[129] M.S. Tonetti, M.A. Imboden, L. Gerber, N.P. Lang, J. Laissue, C. Mueller, Localized
expression of mRNA for phagocyte-specific chemotactic cytokines in human periodontal
infections, Infection and immunity 62 (1994) 4005-4014.
[130] M.S. Tonetti, M.A. Imboden, N.P. Lang, Neutrophil migration into the gingival sulcus is
associated with transepithelial gradients of interleukin-8 and ICAM-1, J Periodontol 69
(1998) 1139-1147.
[131] C. Giannopoulou, I. Cappuyns, A. Mombelli, Effect of smoking on gingival crevicular
fluid cytokine profile during experimental gingivitis, J Clin Periodontol 30 (2003) 996-
1002.
[132] R. Teles, D. Sakellari, F. Teles, A. Konstantinidis, R. Kent, S. Socransky, A. Haffajee,
Relationships among gingival crevicular fluid biomarkers, clinical parameters of
periodontal disease, and the subgingival microbiota, J Periodontol 81 (2010) 89-98.
71
[133] A.I. Dongari-Bagtzoglou, J.L. Ebersole, Increased presence of interleukin-6 (IL-6) and
IL-8 secreting fibroblast subpopulations in adult periodontitis, J Periodontol 69 (1998)
899-910.
[134] J. Gamonal, A. Acevedo, A. Bascones, O. Jorge, A. Silva, Characterization of cellular
infiltrate, detection of chemokine receptor CCR5 and interleukin-8 and RANTES
chemokines in adult periodontitis, J Periodontal Res 36 (2001) 194-203.
[135] L. Forner, C.H. Nielsen, K. Bendtzen, T. Larsen, P. Holmstrup, Increased plasma levels
of IL-6 in bacteremic periodontis patients after scaling, J Clin Periodontol 33 (2006) 724-
729.
[136] G. Brunius, H. Domeij, A. Gustavsson, T. Yucel-Lindberg, Bradykinin upregulates IL-8
production in human gingival fibroblasts stimulated by interleukin-1beta and tumor
necrosis factor alpha, Regulatory peptides 126 (2005) 183-188.
[137] S. Tanabe, C. Bodet, D. Grenier, Treponema denticola lipooligosaccharide activates
gingival fibroblasts and upregulates inflammatory mediator production, J Cell Physiol
216 (2008) 727-731.
[138] A. Sfakianakis, C.E. Barr, D.L. Kreutzer, Localization of the chemokine interleukin-8
and interleukin-8 receptors in human gingiva and cultured gingival keratinocytes, J
Periodontal Res 37 (2002) 154-160.
[139] J. Lindhe, T. Karring, M. Araujo, The Anatomy of Periodontal Tissues, in: J. Lindhe,
N.P. Lang, T. Karring (Eds.), Clinical Periodontology and Implant Dentistry, Blackwell
Publishing Ltd., 2008, Vol. 1, pp. 3-49.
[140] P.D. Arora, M.F. Manolson, G.P. Downey, J. Sodek, C.A. McCulloch, A novel model
system for characterization of phagosomal maturation, acidification, and intracellular
collagen degradation in fibroblasts, J Biol Chem 275 (2000) 35432-35441.
[141] P.D. Arora, C.A. McCulloch, Dependence of collagen remodelling on alpha-smooth
muscle actin expression by fibroblasts, J Cell Physiol 159 (1994) 161-175.
[142] C.M. Overall, J. Sodek, Concanavalin A produces a matrix-degradative phenotype in
human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa
gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of
matrix metalloproteinases, The Journal of biological chemistry 265 (1990) 21141-21151.
[143] C.A. McCulloch, G.C. Knowles, Deficiencies in collagen phagocytosis by human
fibroblasts in vitro: a mechanism for fibrosis?, J Cell Physiol 155 (1993) 461-471.
[144] T.M. Hassell, A.F. Hefti, Drug-induced gingival overgrowth: old problem, new problem,
Crit Rev Oral Biol Med 2 (1991) 103-137.
[145] I. Darby, O. Skalli, G. Gabbiani, Alpha-smooth muscle actin is transiently expressed by
myofibroblasts during experimental wound healing, Laboratory investigation; a journal of
technical methods and pathology 63 (1990) 21-29.
[146] G. Gabbiani, Modulation of fibroblastic cytoskeletal features during wound healing and
fibrosis, Pathology, research and practice 190 (1994) 851-853.
[147] C. Giannopoulou, G. Cimasoni, Functional characteristics of gingival and periodontal
ligament fibroblasts, Journal of dental research 75 (1996) 895-902.
[148] D.S. Tewari, Y. Qian, M. Tewari, J. Pieringer, R.D. Thornton, R. Taub, E.O. Mochan,
Mechanistic features associated with induction of metalloproteinases in human gingival
fibroblasts by interleukin-1, Arch Oral Biol 39 (1994) 657-664.
72
[149] Y.Y. Yang, H.F. Tsai, S.C. Lu, Y.F. Huang, Y.C. Chang, Regulation of tissue inhibitors
of metalloproteinase-1 gene expression by cytokines in human gingival fibroblasts,
Journal of endodontics 28 (2002) 803-805.
[150] T. Kubota, M. Itagaki, C. Hoshino, M. Nagata, T. Morozumi, T. Kobayashi, R. Takagi,
H. Yoshie, Altered gene expression levels of matrix metalloproteinases and their
inhibitors in periodontitis-affected gingival tissue, J Periodontol 79 (2008) 166-173.
[151] M.C. Meikle, R.M. Hembry, J. Holley, C. Horton, C.G. McFarlane, J.J. Reynolds,
Immunolocalization of matrix metalloproteinases and TIMP-1 (tissue inhibitor of
metalloproteinases) in human gingival tissues from periodontitis patients, J Periodontal
Res 29 (1994) 118-126.
[152] H. Takada, J. Mihara, I. Morisaki, S. Hamada, Induction of interleukin-1 and -6 in human
gingival fibroblast cultures stimulated with Bacteroides lipopolysaccharides, Infection
and immunity 59 (1991) 295-301.
[153] S. Takashiba, M. Takigawa, K. Takahashi, F. Myokai, F. Nishimura, T. Chihara, H.
Kurihara, Y. Nomura, Y. Murayama, Interleukin-8 is a major neutrophil chemotactic
factor derived from cultured human gingival fibroblasts stimulated with interleukin-1
beta or tumor necrosis factor alpha, Infection and immunity 60 (1992) 5253-5258.
[154] H.E. Schroeder, R. Page, Lymphocyte-fibroblast interaction in the pathogenesis of
inflammatory gingival disease, Experientia 28 (1972) 1228-1230.
[155] D.H. Maurer, W.E. Collins, J.H. Hanke, M. Van, R.R. Rich, M.S. Pollack, Class II
positive human dermal fibroblasts restimulate cloned allospecific T cells but fail to
stimulate primary allogeneic lymphoproliferation, Human immunology 14 (1985) 245-
258.
[156] D.H. Maurer, J.H. Hanke, E. Mickelson, R.R. Rich, M.S. Pollack, Differential
presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated
dermal fibroblasts, J Immunol 139 (1987) 715-723.
[157] J.S. Pober, T. Collins, M.A. Gimbrone, Jr., R.S. Cotran, J.D. Gitlin, W. Fiers, C.
Clayberger, A.M. Krensky, S.J. Burakoff, C.S. Reiss, Lymphocytes recognize human
vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune
interferon, Nature 305 (1983) 726-729.
[158] D. Abraham, H. Muir, I. Olsen, Adhesion of T and B lymphocytes to fibroblasts in tissue
culture, Immunology 65 (1988) 385-392.
[159] T.H. Piela, J.H. Korn, Lymphocyte-fibroblast adhesion induced by interferon-gamma,
Cellular immunology 114 (1988) 149-160.
[160] T.H. Piela, J.H. Korn, ICAM-1-dependent fibroblast-lymphocyte adhesion: discordance
between surface expression and function of ICAM-1, Cellular immunology 129 (1990)
125-137.
[161] S. Murakami, T. Saho, A. Asari, E. Hino, D. Kasai, Y. Shimabukuro, H. Okada, CD44-
hyaluronate interaction participates in the adherence of T-lymphocytes to gingival
fibroblasts, Journal of dental research 75 (1996) 1545-1552.
[162] S. Murakami, Y. Shimabukuro, T. Saho, E. Hino, D. Kasai, T. Hashikawa, H. Hirano, H.
Okada, Immunoregulatory roles of adhesive interactions between lymphocytes and
gingival fibroblasts, J Periodontal Res 32 (1997) 110-114.
[163] S. Murakami, H. Okada, Lymphocyte-fibroblast interactions, Crit Rev Oral Biol Med 8
(1997) 40-50.
73
[164] S. Murakami, E. Hino, Y. Shimabukuro, T. Nozaki, Y. Kusumoto, T. Saho, F. Hirano, H.
Hirano, H. Okada, Direct interaction between gingival fibroblasts and lymphoid cells
induces inflammatory cytokine mRNA expression in gingival fibroblasts, Journal of
dental research 78 (1999) 69-76.
[165] J.A. Cairns, A.F. Walls, Mast cell tryptase stimulates the synthesis of type I collagen in
human lung fibroblasts, The Journal of clinical investigation 99 (1997) 1313-1321.
[166] S.M. Fitzgerald, S.A. Lee, H.K. Hall, D.S. Chi, G. Krishnaswamy, Human lung
fibroblasts express interleukin-6 in response to signaling after mast cell contact,
American journal of respiratory cell and molecular biology 30 (2004) 585-593.
[167] B.L. Gruber, Mast cells in the pathogenesis of fibrosis, Current rheumatology reports 5
(2003) 147-153.
[168] D.D. Metcalfe, D. Baram, Y.A. Mekori, Mast cells, Physiological reviews 77 (1997)
1033-1079.
[169] S.J. Galli, I. Hammel, Mast cell and basophil development, Current opinion in
hematology 1 (1994) 33-39.
[170] J. Kalesnikoff, S.J. Galli, New developments in mast cell biology, Nature immunology 9
(2008) 1215-1223.
[171] S. Weber, S. Kruger-Krasagakes, J. Grabbe, T. Zuberbier, B.M. Czarnetzki, Mast cells,
International journal of dermatology 34 (1995) 1-10.
[172] T.J.B. Lin, A. D. , Mast cells and eosinophils in mucosal defenses and pathogenesis.,
Mucosal Immunology, eds. Ogra, P. L., Mestecky, J., Lamm, M. E., Strober, W.,
Bienenstock, J. & McGhee, J. R.San Diego, CA: Academic Press. (1999) 469-482.
[173] S. Steinsvoll, T.S. Halstensen, K. Schenck, Extensive expression of TGF-beta1 in
chronically-inflamed periodontal tissue, J Clin Periodontol 26 (1999) 366-373.
[174] A.M. Irani, T.R. Bradford, C.L. Kepley, N.M. Schechter, L.B. Schwartz, Detection of
MCT and MCTC types of human mast cells by immunohistochemistry using new
monoclonal anti-tryptase and anti-chymase antibodies, J Histochem Cytochem 37 (1989)
1509-1515.
[175] L.B. Schwartz, R.A. Lewis, K.F. Austen, Tryptase from human pulmonary mast cells.
Purification and characterization, The Journal of biological chemistry 256 (1981) 11939-
11943.
[176] P.J. Pereira, A. Bergner, S. Macedo-Ribeiro, R. Huber, G. Matschiner, H. Fritz, C.P.
Sommerhoff, W. Bode, Human beta-tryptase is a ring-like tetramer with active sites
facing a central pore, Nature 392 (1998) 306-311.
[177] Y. Fukuoka, L.B. Schwartz, Active monomers of human beta-tryptase have expanded
substrate specificities, International immunopharmacology 7 (2007) 1900-1908.
[178] Q. Peng, A.R. McEuen, R.C. Benyon, A.F. Walls, The heterogeneity of mast cell tryptase
from human lung and skin, European journal of biochemistry / FEBS 270 (2003) 270-
283.
[179] J. Lohi, I. Harvima, J. Keski-Oja, Pericellular substrates of human mast cell tryptase:
72,000 dalton gelatinase and fibronectin, Journal of cellular biochemistry 50 (1992) 337-
349.
[180] V.A. Thomas, C.J. Wheeless, M.S. Stack, D.A. Johnson, Human mast cell tryptase
fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption,
Biochemistry 37 (1998) 2291-2298.
74
[181] M.S. Stack, D.A. Johnson, Human mast cell tryptase activates single-chain urinary-type
plasminogen activator (pro-urokinase), The Journal of biological chemistry 269 (1994)
9416-9419.
[182] B.L. Gruber, M.J. Marchese, K. Suzuki, L.B. Schwartz, Y. Okada, H. Nagase, N.S.
Ramamurthy, Synovial procollagenase activation by human mast cell tryptase
dependence upon matrix metalloproteinase 3 activation, The Journal of clinical
investigation 84 (1989) 1657-1662.
[183] P. Berger, D.W. Perng, H. Thabrew, S.J. Compton, J.A. Cairns, A.R. McEuen, R.
Marthan, J.M. Tunon De Lara, A.F. Walls, Tryptase and agonists of PAR-2 induce the
proliferation of human airway smooth muscle cells, J Appl Physiol 91 (2001) 1372-1379.
[184] L.B. Schwartz, M.S. Kawahara, T.E. Hugli, D. Vik, D.T. Fearon, K.F. Austen,
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase, J
Immunol 130 (1983) 1891-1895.
[185] S.M. Goldstein, J. Leong, L.B. Schwartz, D. Cooke, Protease composition of exocytosed
human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex
distinct from chymase and carboxypeptidase, J Immunol 148 (1992) 2475-2482.
[186] H. Urata, A. Kinoshita, K.S. Misono, F.M. Bumpus, A. Husain, Identification of a highly
specific chymase as the major angiotensin II-forming enzyme in the human heart, The
Journal of biological chemistry 265 (1990) 22348-22357.
[187] M.W. Kofford, L.B. Schwartz, N.M. Schechter, D.R. Yager, R.F. Diegelmann, M.F.
Graham, Cleavage of type I procollagen by human mast cell chymase initiates collagen
fibril formation and generates a unique carboxyl-terminal propeptide, The Journal of
biological chemistry 272 (1997) 7127-7131.
[188] W. Zhao, C.A. Oskeritzian, A.L. Pozez, L.B. Schwartz, Cytokine production by skin-
derived mast cells: endogenous proteases are responsible for degradation of cytokines, J
Immunol 175 (2005) 2635-2642.
[189] M. Jutel, M. Akdis, C.A. Akdis, Histamine, histamine receptors and their role in immune
pathology, Clin Exp Allergy 39 (2009) 1786-1800.
[190] Y. Endo, Simultaneous induction of histidine and ornithine decarboxylases and changes
in their product amines following the injection of Escherichia coli lipopolysaccharide into
mice, Biochemical pharmacology 31 (1982) 1643-1647.
[191] S. Steinsvoll, K. Helgeland, K. Schenck, Mast cells--a role in periodontal diseases?, J
Clin Periodontol 31 (2004) 413-419.
[192] E.P. Naesse, O. Schreurs, K. Helgeland, K. Schenck, S. Steinsvoll, Matrix
metalloproteinases and their inhibitors in gingival mast cells in persons with and without
human immunodeficiency virus infection, J Periodontal Res 38 (2003) 575-582.
[193] N. Di Girolamo, D. Wakefield, In vitro and in vivo expression of interstitial
collagenase/MMP-1 by human mast cells, Developmental immunology 7 (2000) 131-
142.
[194] M. Artuc, B. Hermes, U.M. Steckelings, A. Grutzkau, B.M. Henz, Mast cells and their
mediators in cutaneous wound healing--active participants or innocent bystanders?,
Experimental dermatology 8 (1999) 1-16.
[195] P. Bradding, S.T. Holgate, Immunopathology and human mast cell cytokines, Critical
reviews in oncology/hematology 31 (1999) 119-133.
75
[196] B.M. Henz, M. Maurer, U. Lippert, M. Worm, M. Babina, Mast cells as initiators of
immunity and host defense, Experimental dermatology 10 (2001) 1-10.
[197] P. Sriramarao, W. Anderson, B.A. Wolitzky, D.H. Broide, Mouse bone marrow-derived
mast cells roll on P-selectin under conditions of flow in vivo, Laboratory investigation; a
journal of technical methods and pathology 74 (1996) 634-643.
[198] H. Vliagoftis, D.D. Metcalfe, Characterization of adhesive interactions between mast
cells and laminin isoforms: evidence of a principal role for alpha 6 integrin, Immunology
92 (1997) 553-560.
[199] M. Columbo, B.S. Bochner, G. Marone, Human skin mast cells express functional beta 1
integrins that mediate adhesion to extracellular matrix proteins, J Immunol 154 (1995)
6058-6064.
[200] P. Valent, P. Bettelheim, Cell surface structures on human basophils and mast cells:
biochemical and functional characterization, Advances in immunology 52 (1992) 333-
423.
[201] H. Ochi, W.M. Hirani, Q. Yuan, D.S. Friend, K.F. Austen, J.A. Boyce, T helper cell type
2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation
of human mast cells in vitro, The Journal of experimental medicine 190 (1999) 267-280.
[202] F.H. Martin, S.V. Suggs, K.E. Langley, H.S. Lu, J. Ting, K.H. Okino, C.F. Morris, I.K.
McNiece, F.W. Jacobsen, E.A. Mendiaz, et al., Primary structure and functional
expression of rat and human stem cell factor DNAs, Cell 63 (1990) 203-211.
[203] M. Tsai, T. Takeishi, H. Thompson, K.E. Langley, K.M. Zsebo, D.D. Metcalfe, E.N.
Geissler, S.J. Galli, Induction of mast cell proliferation, maturation, and heparin synthesis
by the rat c-kit ligand, stem cell factor, Proceedings of the National Academy of Sciences
of the United States of America 88 (1991) 6382-6386.
[204] K.M. Zsebo, D.A. Williams, E.N. Geissler, V.C. Broudy, F.H. Martin, H.L. Atkins, R.Y.
Hsu, N.C. Birkett, K.H. Okino, D.C. Murdock, et al., Stem cell factor is encoded at the Sl
locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor, Cell 63 (1990)
213-224.
[205] M. Rottem, J.P. Goff, J.P. Albert, D.D. Metcalfe, The effects of stem cell factor on the
ultrastructure of Fc epsilon RI+ cells developing in IL-3-dependent murine bone marrow-
derived cell cultures, J Immunol 151 (1993) 4950-4963.
[206] A. Iemura, M. Tsai, A. Ando, B.K. Wershil, S.J. Galli, The c-kit ligand, stem cell factor,
promotes mast cell survival by suppressing apoptosis, The American journal of pathology
144 (1994) 321-328.
[207] Y.A. Mekori, C.K. Oh, D.D. Metcalfe, IL-3-dependent murine mast cells undergo
apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand, J Immunol 151
(1993) 3775-3784.
[208] K.B. Madden, J.F. Urban, Jr., H.J. Ziltener, J.W. Schrader, F.D. Finkelman, I.M. Katona,
Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis, J
Immunol 147 (1991) 1387-1391.
[209] E. Schmitt, B. Fassbender, K. Beyreuther, E. Spaeth, R. Schwarzkopf, E. Rude,
Characterization of a T cell-derived lymphokine that acts synergistically with IL 3 on the
growth of murine mast cells and is identical with IL 4, Immunobiology 174 (1987) 406-
419.
76
[210] J.P. Gorski, T.E. Hugli, H.J. Muller-Eberhard, C4a: the third anaphylatoxin of the human
complement system, Proceedings of the National Academy of Sciences of the United
States of America 76 (1979) 5299-5302.
[211] T.E. Hugli, H.J. Muller-Eberhard, Anaphylatoxins: C3a and C5a, Advances in
immunology 26 (1978) 1-53.
[212] S.J. Galli, J. Kalesnikoff, M.A. Grimbaldeston, A.M. Piliponsky, C.M. Williams, M.
Tsai, Mast cells as "tunable" effector and immunoregulatory cells: recent advances,
Annual review of immunology 23 (2005) 749-786.
[213] S.J. Galli, M. Grimbaldeston, M. Tsai, Immunomodulatory mast cells: negative, as well
as positive, regulators of immunity, Nature reviews 8 (2008) 478-486.
[214] J. Rivera, A.M. Gilfillan, Molecular regulation of mast cell activation, The Journal of
allergy and clinical immunology 117 (2006) 1214-1225; quiz 1226.
[215] S.N. Abraham, R. Malaviya, Mast cell modulation of the innate immune response to
enterobacterial infection, Advances in experimental medicine and biology 479 (2000) 91-
105.
[216] I. Bot, S.C. de Jager, A. Zernecke, K.A. Lindstedt, T.J. van Berkel, C. Weber, E.A.
Biessen, Perivascular mast cells promote atherogenesis and induce plaque destabilization
in apolipoprotein E-deficient mice, Circulation 115 (2007) 2516-2525.
[217] P.T. Kovanen, Mast cells and degradation of pericellular and extracellular matrices:
potential contributions to erosion, rupture and intraplaque haemorrhage of atherosclerotic
plaques, Biochemical Society transactions 35 (2007) 857-861.
[218] J. Sun, G.K. Sukhova, P.J. Wolters, M. Yang, S. Kitamoto, P. Libby, L.A. MacFarlane, J.
Mallen-St Clair, G.P. Shi, Mast cells promote atherosclerosis by releasing
proinflammatory cytokines, Nature medicine 13 (2007) 719-724.
[219] A.C. Batista, C.O. Rodini, V.S. Lara, Quantification of mast cells in different stages of
human periodontal disease, Oral Dis 11 (2005) 249-254.
[220] M. Gunhan, H. Bostanci, O. Gunhan, M. Demiriz, Mast cells in periodontal disease, Ann
Dent 50 (1991) 25-29.
[221] U. Zappa, M. Reinking-Zappa, H. Graf, D. Case, Cell populations associated with active
probing attachment loss, J Periodontol 63 (1992) 748-752.
[222] U. Zappa, M. Reinking-Zappa, H. Graf, M. Espeland, Cell populations and episodic
periodontal attachment loss in humans, J Clin Periodontol 18 (1991) 508-515.
[223] I. Rauter, M.T. Krauth, K. Westritschnig, F. Horak, S. Flicker, A. Gieras, A. Repa, N.
Balic, S. Spitzauer, J. Huss-Marp, K. Brockow, U. Darsow, H. Behrendt, J. Ring, F.
Kricek, P. Valent, R. Valenta, Mast cell-derived proteases control allergic inflammation
through cleavage of IgE, The Journal of allergy and clinical immunology 121 (2008) 197-
202.
[224] M.A. Grimbaldeston, S. Nakae, J. Kalesnikoff, M. Tsai, S.J. Galli, Mast cell-derived
interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with
ultraviolet B, Nature immunology 8 (2007) 1095-1104.
[225] K. Rakusan, K. Sarkar, Z. Turek, P. Wicker, Mast cells in the rat heart during normal
growth and in cardiac hypertrophy, Circulation research 66 (1990) 511-516.
[226] J.A. Rhodin, H. Fujita, Capillary growth in the mesentery of normal young rats. Intravital
video and electron microscope analyses, Journal of submicroscopic cytology and
pathology 21 (1989) 1-34.
77
[227] A.E. Jakobsson, Angiogenesis induced by mast cell secretion in rat peritoneal connective
tissue is a process of three phases, Microvascular research 47 (1994) 252-269.
[228] J. Sorbo, A. Jakobsson, K. Norrby, Mast-cell histamine is angiogenic through receptors
for histamine1 and histamine2, International journal of experimental pathology 75 (1994)
43-50.
[229] R.G. Azizkhan, J.C. Azizkhan, B.R. Zetter, J. Folkman, Mast cell heparin stimulates
migration of capillary endothelial cells in vitro, The Journal of experimental medicine
152 (1980) 931-944.
[230] R.M. Marks, W.R. Roche, M. Czerniecki, R. Penny, D.S. Nelson, Mast cell granules
cause proliferation of human microvascular endothelial cells, Laboratory investigation; a
journal of technical methods and pathology 55 (1986) 289-294.
[231] J.R. Starkey, P.K. Crowle, S. Taubenberger, Mast-cell-deficient W/Wv mice exhibit a
decreased rate of tumor angiogenesis, International journal of cancer 42 (1988) 48-52.
[232] L.F. Fajardo, H.H. Kwan, J. Kowalski, S.D. Prionas, A.C. Allison, Dual role of tumor
necrosis factor-alpha in angiogenesis, The American journal of pathology 140 (1992)
539-544.
[233] C.J. Meininger, B.R. Zetter, Mast cells and angiogenesis, Seminars in cancer biology 3
(1992) 73-79.
[234] B.L. Gruber, M.J. Marchese, R. Kew, Angiogenic factors stimulate mast-cell migration,
Blood 86 (1995) 2488-2493.
[235] M.M. Friedman, M. Kaliner, In situ degranulation of human nasal mucosal mast cells:
ultrastructural features and cell-cell associations, The Journal of allergy and clinical
immunology 76 (1985) 70-82.
[236] B.F. Gibbs, J. Wierecky, P. Welker, B.M. Henz, H.H. Wolff, J. Grabbe, Human skin mast
cells rapidly release preformed and newly generated TNF-alpha and IL-8 following
stimulation with anti-IgE and other secretagogues, Experimental dermatology 10 (2001)
312-320.
[237] C.G. Larsen, A.O. Anderson, E. Appella, J.J. Oppenheim, K. Matsushima, The
neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes, Science
(New York, N.Y 243 (1989) 1464-1466.
[238] A. Moller, B.M. Henz, A. Grutzkau, U. Lippert, Y. Aragane, T. Schwarz, S. Kruger-
Krasagakes, Comparative cytokine gene expression: regulation and release by human
mast cells, Immunology 93 (1998) 289-295.
[239] V. Rumsaeng, W.W. Cruikshank, B. Foster, C. Prussin, A.S. Kirshenbaum, T.A. Davis,
H. Kornfeld, D.M. Center, D.D. Metcalfe, Human mast cells produce the CD4+ T
lymphocyte chemoattractant factor, IL-16, J Immunol 159 (1997) 2904-2910.
[240] V. Rumsaeng, H. Vliagoftis, C.K. Oh, D.D. Metcalfe, Lymphotactin gene expression in
mast cells following Fc(epsilon) receptor I aggregation: modulation by TGF-beta, IL-4,
dexamethasone, and cyclosporin A, J Immunol 158 (1997) 1353-1360.
[241] N. Tedla, H.W. Wang, H.P. McNeil, N. Di Girolamo, T. Hampartzoumian, D. Wakefield,
A. Lloyd, Regulation of T lymphocyte trafficking into lymph nodes during an immune
response by the chemokines macrophage inflammatory protein (MIP)-1 alpha and MIP-1
beta, J Immunol 161 (1998) 5663-5672.
[242] S. Kruger-Krasagakes, A. Grutzkau, R. Baghramian, B.M. Henz, Interactions of
immature human mast cells with extracellular matrix: expression of specific adhesion
78
receptors and their role in cell binding to matrix proteins, The Journal of investigative
dermatology 106 (1996) 538-543.
[243] H.W. Wang, N. Tedla, A.R. Lloyd, D. Wakefield, P.H. McNeil, Mast cell activation and
migration to lymph nodes during induction of an immune response in mice, The Journal
of clinical investigation 102 (1998) 1617-1626.
[244] S.R. Au, K. Au, G.C. Saggers, N. Karne, H.P. Ehrlich, Rat mast cells communicate with
fibroblasts via gap junction intercellular communications, Journal of cellular
biochemistry 100 (2007) 1170-1177.
[245] K.E. Moyer, G.C. Saggers, H.P. Ehrlich, Mast cells promote fibroblast populated
collagen lattice contraction through gap junction intercellular communication, Wound
Repair Regen 12 (2004) 269-275.
[246] S.J. Galli, K.M. Zsebo, E.N. Geissler, The kit ligand, stem cell factor, Advances in
immunology 55 (1994) 1-96.
[247] C. Hogaboam, S.L. Kunkel, R.M. Strieter, D.D. Taub, P. Lincoln, T.J. Standiford, N.W.
Lukacs, Novel role of transmembrane SCF for mast cell activation and eotaxin
production in mast cell-fibroblast interactions, J Immunol 160 (1998) 6166-6171.
[248] T. Yamamoto, K. Hartmann, B. Eckes, T. Krieg, Role of stem cell factor and monocyte
chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis,
Journal of dermatological science 26 (2001) 106-111.
[249] H.P. Kiener, R. Hofbauer, M. Tohidast-Akrad, S. Walchshofer, K. Redlich, P. Bitzan, S.
Kapiotis, G. Steiner, J.S. Smolen, P. Valent, Tumor necrosis factor alpha promotes the
expression of stem cell factor in synovial fibroblasts and their capacity to induce mast
cell chemotaxis, Arthritis and rheumatism 43 (2000) 164-174.
[250] B.L. Gruber, R.R. Kew, A. Jelaska, M.J. Marchese, J. Garlick, S. Ren, L.B. Schwartz,
J.H. Korn, Human mast cells activate fibroblasts: tryptase is a fibrogenic factor
stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis, J
Immunol 158 (1997) 2310-2317.
[251] M. Abe, M. Kurosawa, O. Ishikawa, Y. Miyachi, Effect of mast cell-derived mediators
and mast cell-related neutral proteases on human dermal fibroblast proliferation and type
I collagen production, The Journal of allergy and clinical immunology 106 (2000) S78-
84.
[252] I.A. Akers, M. Parsons, M.R. Hill, M.D. Hollenberg, S. Sanjar, G.J. Laurent, R.J.
McAnulty, Mast cell tryptase stimulates human lung fibroblast proliferation via protease-
activated receptor-2, Am J Physiol Lung Cell Mol Physiol 278 (2000) L193-201.
[253] J. Gailit, M.J. Marchese, R.R. Kew, B.L. Gruber, The differentiation and function of
myofibroblasts is regulated by mast cell mediators, The Journal of investigative
dermatology 117 (2001) 1113-1119.
[254] E. Garbuzenko, A. Nagler, D. Pickholtz, P. Gillery, R. Reich, F.X. Maquart, F. Levi-
Schaffer, Human mast cells stimulate fibroblast proliferation, collagen synthesis and
lattice contraction: a direct role for mast cells in skin fibrosis, Clin Exp Allergy 32 (2002)
237-246.
[255] C.M. Skold, Y. Ohkuni, X.D. Liu, R. Numerof, S.I. Rennard, Co-cultured human mast
cells stimulate fibroblast-mediated contraction of collagen gels, Inflammation 25 (2001)
47-51.
79
[256] T. Yamamoto, K. Hartmann, B. Eckes, T. Krieg, Mast cells enhance contraction of three-
dimensional collagen lattices by fibroblasts by cell-cell interaction: role of stem cell
factor/c-kit, Immunology 99 (2000) 435-439.
[257] M. Artuc, U.M. Steckelings, B.M. Henz, Mast cell-fibroblast interactions: human mast
cells as source and inducers of fibroblast and epithelial growth factors, The Journal of
investigative dermatology 118 (2002) 391-395.
[258] S. Nakano, T. Mishiro, S. Takahara, H. Yokoi, D. Hamada, K. Yukata, Y. Takata, T.
Goto, H. Egawa, S. Yasuoka, H. Furouchi, K. Hirasaka, T. Nikawa, N. Yasui, Distinct
expression of mast cell tryptase and protease activated receptor-2 in synovia of
rheumatoid arthritis and osteoarthritis, Clinical rheumatology 26 (2007) 1284-1292.
[259] C. van Kooten, J. Banchereau, CD40-CD40 ligand, Journal of leukocyte biology 67
(2000) 2-17.
[260] G.D. Sempowski, P.R. Chess, A.J. Moretti, J. Padilla, R.P. Phipps, T.M. Blieden, CD40
mediated activation of gingival and periodontal ligament fibroblasts, J Periodontol 68
(1997) 284-292.
[261] H.J. Cao, H.S. Wang, Y. Zhang, H.Y. Lin, R.P. Phipps, T.J. Smith, Activation of human
orbital fibroblasts through CD40 engagement results in a dramatic induction of
hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights
into potential pathogenic mechanisms of thyroid-associated ophthalmopathy, The Journal
of biological chemistry 273 (1998) 29615-29625.
[262] G.D. Sempowski, P.R. Chess, R.P. Phipps, CD40 is a functional activation antigen and
B7-independent T cell costimulatory molecule on normal human lung fibroblasts, J
Immunol 158 (1997) 4670-4677.
[263] R.C. Page, S. Offenbacher, H.E. Schroeder, G.J. Seymour, K.S. Kornman, Advances in
the pathogenesis of periodontitis: summary of developments, clinical implications and
future directions, Periodontology 2000 14 (1997) 216-248.
[264] T.M. Hassell, Tissues and cells of the periodontium, Periodontology 2000 3 (1993) 9-38.
[265] N. Pender, C.A. McCulloch, Quantitation of actin polymerization in two human
fibroblast sub-types responding to mechanical stretching, Journal of cell science 100 ( Pt
1) (1991) 187-193.
[266] J.H. Butterfield, D. Weiler, G. Dewald, G.J. Gleich, Establishment of an immature mast
cell line from a patient with mast cell leukemia, Leukemia research 12 (1988) 345-355.
[267] W. Lee, J. Sodek, C.A. McCulloch, Role of integrins in regulation of collagen
phagocytosis by human fibroblasts, J Cell Physiol 168 (1996) 695-704.
[268] T.Y. El Sayegh, P.D. Arora, K. Ling, C. Laschinger, P.A. Janmey, R.A. Anderson, C.A.
McCulloch, Phosphatidylinositol-4,5 bisphosphate produced by PIP5KIgamma regulates
gelsolin, actin assembly, and adhesion strength of N-cadherin junctions, Molecular
biology of the cell 18 (2007) 3026-3038.
[269] M. Lambert, F. Padilla, R.M. Mege, Immobilized dimers of N-cadherin-Fc chimera
mimic cadherin-mediated cell contact formation: contribution of both outside-in and
inside-out signals, Journal of cell science 113 ( Pt 12) (2000) 2207-2219.
[270] D.C. Spray, M.V. Bennett, Physiology and pharmacology of gap junctions, Annual
review of physiology 47 (1985) 281-303.
[271] J.R. Allport, Y.C. Lim, J.M. Shipley, R.M. Senior, S.D. Shapiro, N. Matsuyoshi, D.
Vestweber, F.W. Luscinskas, Neutrophils from MMP-9- or neutrophil elastase-deficient
80
mice show no defect in transendothelial migration under flow in vitro, Journal of
leukocyte biology 71 (2002) 821-828.
[272] C.X. Sun, G.P. Downey, F. Zhu, A.L. Koh, H. Thang, M. Glogauer, Rac1 is the small
GTPase responsible for regulating the neutrophil chemotaxis compass, Blood 104 (2004)
3758-3765.
[273] S.A. Chong, W. Lee, P.D. Arora, C. Laschinger, E.W. Young, C.A. Simmons, M.
Manolson, J. Sodek, C.A. McCulloch, Methylglyoxal inhibits the binding step of
collagen phagocytosis, The Journal of biological chemistry 282 (2007) 8510-8520.
[274] K. Ko, P. Arora, W. Lee, C. McCulloch, Biochemical and functional characterization of
intercellular adhesion and gap junctions in fibroblasts, Am J Physiol Cell Physiol 279
(2000) C147-157.
[275] G.S. Goldberg, J.F. Bechberger, C.C. Naus, A pre-loading method of evaluating gap
junctional communication by fluorescent dye transfer, BioTechniques 18 (1995) 490-497.
[276] A.C. Charles, C.C. Naus, D. Zhu, G.M. Kidder, E.R. Dirksen, M.J. Sanderson,
Intercellular calcium signaling via gap junctions in glioma cells, The Journal of cell
biology 118 (1992) 195-201.
[277] M.S. Kim, W.K. Lim, R.K. Park, T. Shin, Y.H. Yoo, S.H. Hong, N.H. An, H.M. Kim,
Involvement of mitogen-activated protein kinase and NF-kappaB activation in Ca2+-
induced IL-8 production in human mast cells, Cytokine 32 (2005) 226-233.
[278] J.A. Wedzicha, G.C. Donaldson, Exacerbations of chronic obstructive pulmonary disease,
Respiratory care 48 (2003) 1204-1213; discussion 1213-1205.
[279] K.A. Papadakis, Chemokines in inflammatory bowel disease, Current allergy and asthma
reports 4 (2004) 83-89.
[280] M.P. Gelderman, R. Stuart, D. Vigerust, S. Fuhrmann, D.L. Lefkowitz, R.C. Allen, S.S.
Lefkowitz, S. Graham, Perpetuation of inflammation associated with experimental
arthritis: the role of macrophage activation by neutrophilic myeloperoxidase, Mediators
of inflammation 7 (1998) 381-389.
[281] M.G. O'Riordain, J.A. Ross, K.C. Fearon, J. Maingay, M. Farouk, O.J. Garden, D.C.
Carter, Insulin and counterregulatory hormones influence acute-phase protein production
in human hepatocytes, The American journal of physiology 269 (1995) E323-330.
[282] S.J. Wigmore, T.S. Walsh, A. Lee, J.A. Ross, Pro-inflammatory cytokine release and
mediation of the acute phase protein response in fulminant hepatic failure, Intensive care
medicine 24 (1998) 224-229.
[283] N.A. Boyd, A.R. Bradwell, R.A. Thompson, Quantitation of vitronectin in serum:
evaluation of its usefulness in routine clinical practice, Journal of clinical pathology 46
(1993) 1042-1045.
[284] I. Schvartz, D. Seger, S. Shaltiel, Vitronectin, The international journal of biochemistry
& cell biology 31 (1999) 539-544.
[285] H.R. Petty, R.F. Todd, 3rd, Integrins as promiscuous signal transduction devices,
Immunology today 17 (1996) 209-212.
[286] H.G. Drexler, R.A. MacLeod, Malignant hematopoietic cell lines: in vitro models for the
study of mast cell leukemia, Leukemia research 27 (2003) 671-676.
[287] N.M. Kumar, N.B. Gilula, The gap junction communication channel, Cell 84 (1996) 381-
388.
81
[288] D. Salomon, J.H. Saurat, P. Meda, Cell-to-cell communication within intact human skin,
The Journal of clinical investigation 82 (1988) 248-254.
[289] V. Serre-Beinier, C. Mas, A. Calabrese, D. Caton, J. Bauquis, D. Caille, A. Charollais, V.
Cirulli, P. Meda, Connexins and secretion, Biology of the cell / under the auspices of the
European Cell Biology Organization 94 (2002) 477-492.
[290] L.S. Musil, D.A. Goodenough, Biochemical analysis of connexin43 intracellular
transport, phosphorylation, and assembly into gap junctional plaques, The Journal of cell
biology 115 (1991) 1357-1374.
[291] H. Vliagoftis, A.M. Hutson, S. Mahmudi-Azer, H. Kim, V. Rumsaeng, C.K. Oh, R.
Moqbel, D.D. Metcalfe, Mast cells express connexins on their cytoplasmic membrane,
The Journal of allergy and clinical immunology 103 (1999) 656-662.
[292] S.M. Oliani, A.P. Girol, R.L. Smith, Gap junctions between mast cells and fibroblasts in
the developing avian eye, Acta anatomica 154 (1995) 267-271.
[293] S. Boitano, E.R. Dirksen, M.J. Sanderson, Intercellular propagation of calcium waves
mediated by inositol trisphosphate, Science (New York, N.Y 258 (1992) 292-295.
[294] G. Inesi, Y. Sagara, Thapsigargin, a high affinity and global inhibitor of intracellular
Ca2+ transport ATPases, Archives of biochemistry and biophysics 298 (1992) 313-317.
[295] M. Montero, J. Alvarez, J. Garcia-Sancho, Agonist-induced Ca2+ influx in human
neutrophils is secondary to the emptying of intracellular calcium stores, The Biochemical
journal 277 ( Pt 1) (1991) 73-79.
[296] K.S. Ko, P.D. Arora, V. Bhide, A. Chen, C.A. McCulloch, Cell-cell adhesion in human
fibroblasts requires calcium signaling, Journal of cell science 114 (2001) 1155-1167.